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The limited supply of natural resources and the impact on environmental 
pollution have been problems for the pharmaceutical industry for decades. To 
address these problems, many research endeavors to develop green and 
sustainable manufacturing processes have been carried out. One of the recent 
focuses is on multicomponent reactions (MCRs), which allow the quick 
assembly of several simple components into complex structures in one pot. 
Among MCRs, electrophilic MCRs have been less reported, partly because of 
the common incompatibility of electrophiles with the other components. This 
thesis mainly describes my research on bromonium ion induced MCRs. 
 
Chapter 1 of this thesis will introduce cohalogenation reactions, its application 
in the total synthesis of natural product and the recent advance in asymmetric 
organocatalytic cohalogenation. Thereafter, recently advances in halonium ion 
induced cyclic ether ring expansion or opening reaction and aziridine ring 
expansion reaction will be described in details. 
 
Chapter 2 will discuss the seminal work on electrophilic aminoalkoxylation of 
oleﬁns. After that, an efficient MCR was developed using epichlorohydrin, an 
olefin, nosyl amide, and N-bromosuccinimide, giving the halogenated 
products with high regioselectivity. The product could be readily transferred to 
2,2,6-trisubstituted morpholines, which contained methylene chloride handles 
for derivatization.  
VIII 
 
Chapter 3 will describe the synthetic applications of bromonium ion induced 
epoxide ring opening reaction. A 2,6,6-trisubstituted morpholine working as 
carnitine acetyltransferase inhibitor was synthesized using this strategy. In 
addition, formal synthesis of Reboxetine was accomplished by using ethylene 
as the olefinic partner.  This approach not only provides an efficient approach 
towards biologically relevant 2-subsituted morpholine systems, but also offers 
flexibility in making drug analogues for further biological studies. 
 
Chapter 4 will revisit bromonium ion induced MCR, but using aziridine 
instead of epoxide. A novel multicomponent, bromonium ion induced 
aminocyclization-aziridine ring expansion reaction was developed. The 
resulting enantiopure azepanes could be utilized in the preparation of 
functionalized piperidines and rigid amine systems. 
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The increasing demand for new chemical entities urges synthetic chemists to 
pursue high yielding, efficient, selective (chemo-, regio-, diastereo-, and 
enantioselective) and environmentally benign reactions. Multicomponent 
reactions (MCRs) are convergent chemical processes in which more than two 
starting materials are combined into a new product in one-pot procedures.
1
 
This strategy benefits from high level of atom economy while avoiding time-
consuming isolation and puriﬁcation of synthetic intermediates, which 
provides a possible solution for ideal synthesis.
2
 These one-pot processes are 
highly efficient to construct the scaffold of natural products and diverse drug-
like molecules, which make the strategy valuable in modern organic synthesis 
(target-oriented)
3




Although the first documented multicomponent reaction, Strecker amino acid 
synthesis
5
, appeared as early as in 1850, multicomponent reaction strategies 
remained underexploited for many decades until I. Ugi’s pioneering 
contribution with his discovery of novel isocyanide-based four components 
reaction in 1959.
6
 As a matter of fact, due to its unique reactivity, isocyanide 
based multicomponent reactions are the most extensively studied area of 
MCRs and widely applied in field of organic synthesis.
1b, 7
 Due to its power to 
construct amino acid and polypeptide, Ugi four-component reaction was 
utilized in the late stage as one of the key steps to the total synthesis of (-)-
muraymycin D2 (1.1),
8
 a naturally occurring antibiotic, and its epimer, due to 




Scheme 1.1 Ugi Four-Component Approach to (-)-Muraymycin D2 
 
This reaction could also be easily applied in one pot for the preparation of 
Xylocaine (1.2), a commonly used local anesthetic drug
4c
. The in situ 
generated water traps nitrilium ion intermediate to give the -amino 
carboxamide product. Subsequently, in excess of 12 other molecules based on 
the -amino carboxamide scaffold were marketed by a variety of 
pharmaceutical companies, some of which are shown in Scheme 1.2. 
 
With the rapid development of molecular biology and high-throughput 
biological screening, the demand on the number and the quality of small 
molecules for drug discovery has increased enormously. As a powerful tool 
for producing diverse arrays of compounds, often in one step and high yield, 
combined with their nature for easy automated operation, the popularity of 
MCRs has literally exploded since the advent of combinatorial chemistry in 
the late 20
th
 century. In contrast to target-oriented synthesis, which aims to 
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prepare a specific target compound, the diversity-oriented synthesis addresses 
both diversity and complexity. Due to the virtue of their inherent convergence 
and high productivity, together with their exploratory and complexity-
generating power, multicomponent reactions thus have naturally become a 
rapidly evolving ﬁeld of research and have attracted the attention of both 
academic and industrial scientists.  
 
Scheme 1.2 Ugi’s Strategy to Xylocaine and Its Analogues 
 
Among multicomponent reactions, however, electrophilic multicomponent 
reactions are less reported, probably due to the common incompatibility of 
electrophiles with other components. Our interest in the formation of carbon-
halogen bond drives us into the field of halogen induced olefin 





In the following sections, halonium ion induced cohalogenation reaction will 
be reviewed. Main effort, however, will be focused on halonium ion induced 
cyclic ether ring expansion/opening reaction and aziridine ring expansion 
reaction.  
 
1.1 Cohalogenation Reaction 
 
Electrophilic addition of halogen to alkene is a very general organic reaction 
with exceptional high chemo-, regio- and stereoselectivity. Halonium ions 
(Figure 1.1), in which the positively charged halogens (F, Cl, Br, and I) are 
attached to two carbon atoms through three-center bonds, were initially 
proposed in 1937 by Roberts and Kimball to account for the observed high 
trans stereoselectivity. 
9
 The presence of halonium ion was further supported 
by the seminal work of Olah et al. through the observation of various 3-




 In 1994, the cyclic 
bromonium ion and iodonium ion were structurally characterized by B.S. 
Brown et al. using X-ray crystallography,
11
 which provided valuable and solid 
evidence for further researches on cohalogenation. Chloronium ions are 
somewhat less well documented, although some remarkably stable examples 
have recently been synthesized.
12





Figure 1.1 Examples of Halonium Ions 
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For the mechanism of the halofunctionalization, the electrophilic addition of 
halogen source to alkene will first generate a halonium intermediate, which 
could then be captured by a suitable nucleophile to open the three-membered 
halonium ring to yield the product with a 1,2-anti relationship between the 
halogen and the nucleophile (Scheme 1.3).  
 
Scheme 1.3 Generally Accepted Mechanism of Halofunctionalization 
 
The reliability of the 1,2-anti relationship between the halogen and the 
nucleophile has led to widespread adoption in various synthesis. In the 
presence of external nucleophiles such as water, alcohol, ether, carboxylic acid, 
DMF, DMSO and acetonitrile, they will compete with halide ion leading to 
competitive attacked product. This process, termed cohalogenation, constitutes 
one of the largest classes of reaction used to form carbon-heteroatom bond 
chemo-, regio- and stereoselectively. 
 
Some comprehensive reviews on cohalogenation reaction are already 
available.
14
 In the following part, examples of their applications in the total 
synthesis of natural products in recent years will be presented; recent advances 
in catalytic asymmetric cohalogenation reactions will also be covered.  
 
1.1.1 oxygen as nucleophile 
Water: The participation of water in electrophilic halogenations was 
thoroughly studied and the halohydrin obtained was often applied in the 
preparation of epoxide. Since its discovery, this reaction has been used 
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extensively in organic synthesis, and is still a good complement to the direct 
epoxidation of alkenes. For example, in the last stage of the total synthesis of 
(±)-codeine (1.3), treatment of 1.4 with DBDMH gave 1.5 (concomitant 
bromination at C2), which on exposure to KOH/dioxane/reﬂux resulted in the 
-epoxide 1.615 (Scheme 1.4). This strategy was applied because direct 
epoxidation of the 6,7-double bond in 1.4, and similar substrates, proceeds 
from the least hindered face to give the -epoxide, which eventually requires 
stereochemical inversion at C-6. 
 
Scheme 1.4 Conversion of Bromohydrin to Epoxide in the Total Synthesis 
of (±)-Codeine 
 
Carboxylic acid: Carboxylic acids were extensively used as the external 
nucleophiles in electrophilic activation of alkenes, both intermolecularly and 
intramolecularly. In the total synthesis of (+)-bromoxone (1.7) reported by V. 
Schapiro.
16
 The key intermediate 1.9 was prepared from 1.8 by 




Scheme 1.5 Acetoxyiodonation in the Total Synthesis of (+)-Bromoxone 
 
In the years since its discovery in the early 1900s, halolactonization has 
proven to be a versatile reaction in organic synthesis, allowing facile 
formation of small or medium ring size lactones. In the total synthesis of (±)-
Aplykurodinone-1 (1.10), iodolactonization was utilized to construct the γ-
lactone to the cis-fused hydrindanone.
17
 The C1 fragment was cleaved via a 
hydrolysis-retro-aldol sequence following exposure of 1.11 to the action of 
K2CO3 in water at 100 °C. Subsequent iodolactonization of the resultant 
carboxylic acid (1.12) was accomplished in one pot in 75% yield to provide 
1.13, which could be transformed in two steps to the tricyclic core (1.14) of 
Aplykurodinone-1 (Scheme 1.6). 
 
Scheme 1.6 Iodolactonation in the Total Synthesis of Aplykurodinone-1 
 
With the rapid development of organocatalysis in recent years, a series of 
catalysts have been utilized to fulfill the catalytic asymmetric 
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halolactonization reaction.  These organocatalysts are summarized in Figure 
1.2. 
 
Figure 1.2 Organocatalysts for Enantioselective Halolactonization 
 
The ﬁrst example of catalytic, enantioselective halolactonization was disclosed 
by Borhan group
18
. (DHQD)2PHAL (1.15) served as the catalyst, DCDPH was 
used as chlorine source. It was proposed that the interaction between the 
tertiary amine of the catalyst and DCDPH was a crucial element in the 




One of the early reports of enantioselective bromolactonization came from 
Tang group
19
. Quinine derived tosyl urea (1.16) was used as the chiral 
organocatalyst for the bromolactonization of Z-1,3-enynes. The authors 
proposed a dual activation mode where NBS was activated via a hydrogen 
bonding with the NH groups of the urea while the carboxylic acid was 
deprotonated by the tertiary amine. 
 
Another different solution was offered by our laboratory with a class of 
amino-thiocarbamate cinchona alkaloid catalysts, such as 1.17
20
. The amino-
thiocarbamate part served as both a Lewis base
21
 and a hydrogen-bond donor 
to induce a chiral bromonium ion.  
 
Another competent chiral organocatalyst for bromolactonization came in the 
form of the C3-symmetric trisimidazoline (1.18) reported by Fujioka
22
. 
Mechanistically, they found that the presence of the three imidazoline units to 
be crucial to achieve high enantioselectivity. 
 
A novel bifunctional catalyst derived from BINOL (1.19) was developed by S. 
F. Martin
23
. It promoted the highly enantioselective bromolactonizations of a 
number of structurally distinct unsaturated acids. The catalyst was also 




A highly enantioselective iodolactonization of 5-hexenoic acids was achieved 
using a tertiary aminourea-catalyst (1.20) from E. N. Jacobsen
25
. The use of 
catalytic iodine in this process was critical to enhancing both the reactivity and 
11 
 
enantioselectivity of the stoichiometric I
+
 source. The mechanism was 
proposed to involve binding of an iodonium imidate intermediate by the H-
bond donor catalyst. 
 
A distinctive hydrogen-bond-catalyzed enantioselective iodolactonization 
using chiral proton (1.21) catalysis was discovered by J. N. Johnston group
26
. 
The achiral counterion of the polar ionic hydrogen bond can be used to 
optimize the enantioselection, offering an innovative tool for the study of 
electrophilic halonium ion-initiated reactions. 
 
In comparison to the halolactonization, the intermolecular format has proven a 
tougher problem to tackle. In a recent report, a promising enantioselective 
intermolecular bromoesterification was disclosed.
27
 Using chiral phosphoric 
acid catalyst (1.22), promising enantioselectivities could be obtained. The 
yields were however low due to the catalyst acting as a competitive 
nucleophile in opening the bromonium intermediate. 
 
Another highly enantioselective intermolecular bromoesteriﬁcation of allylic 
sulfonamides was achieved by W. Tang group using (DHQD)2PHAL as the 
catalyst.
28
 Both C–O and C–Br bonds were introduced enantioselectively in 
this oleﬁn addition reaction. The sulfonamide NH directing group is important 
for both the reactivity and enantioselectivity. 
 
Alcohol: Usually, alcohols constitute suitable nucleophiles and have been used 
for a long time as a co-reactant in halogenation reactions. Haloetheriﬁcations 
12 
 
to form halo-cyclicether ring is a well-documented operation in the total 
syntheses of various natural products. For example, in the total synthesis of 
Gambieric Acid A, The tetrahydrofuran A ring was established by the 
treatment of 1.23 with NBS to promote stereoselective bromoetheriﬁcation to 
deliver bromide 1.24 in 97% yield as a single stereoisomer
29
 (Scheme 1.7).  
 
Scheme 1.7 Synthesis of A Ring Fragment by Stereoselective 
Bromoetheriﬁcation 
 
Enantioselective haloetherifications were reported by several groups using 
chiral phosphoric acid derivatives and cinchona alkaloid derivatives as catalyst. 
These organocatalysts were shown in Figure 1.3. 
 
Figure 1.3 Organocatalysts for Enantioselective Haloetherifications 
 
U. Hennecke and co-workers were the first to report the desymmetrization of 
1,8-oct-4-ene-diols with the chiral phosphate catalyst 1.25.
30
  While modest 
enantioselectivity was achieved with NBS, much higher enantioselectivity was 




Later on, more highly enantioselective bromoetherifications were reported by 
Y. Shi and co-workers. They utilized NBS as the bromine source and chiral 
phosphoric acid 1.26 as the catalyst to transfer various γ-hydroxy-alkenes to 2-
substituted tetrahydrofurans with generally good yields and 
enantioselectivity.
31
 In addition, they were also able to apply substrates with 
nitrogen nucleophile to the catalytic protocol.  
 
A binary catalyst system was reported by S. E. Denmark for the 
enantioselective bromocycloetherification of 5-arylpentenols.
32
 In his case, the 
combination of an achiral Lewis base (triphenylphosphine sulphide) and a 
chiral Brønsted acid was essential to afford good enantioselectivities for the 
cyclization of Z configured 5-arylpentenols to form 
bromomethyltetrahydrofuran. 
 
An enantioselective 5-endo chloroetherification of homoallylic alcohols was 
reported by W. Sun.
33
 This transformation was catalyzed by the chiral 
quaternary ammonium salts (1.27) derived from cinchonine, which provided 
ready access to -chlorotetrahydrofurans in high enantioselectivities. 
 
Cyclic ether: This will be discussed in details in Section 1.2. 
 
1.1.2 nitrogen as nucleophile 
Compared with organocatalytic enantioselective O-type halocyclization, the 




The amino-thiocarbamate catalysts  developed by our group were also found 
to be able to perform the enantioselective bromoaminocyclization of a variety 
of olefinic amides
34
. One of the essential requirements for this reaction is the 
presence of the nosyl substituents. The NH of the 4-nosyl amide is then 
sufficiently acidic for the reaction to take place smoothly in an 
enantioselective fashion. It was proposed that the catalyst (1.28, Figure 1.4) 
proceeds via a dual activation mode. The sulfur atom in the catalyst is believed 
to act as a Lewis base activator of bromine while the amine may interact with 
nucleophile via an acid-base interaction. 
 
Figure 1.4 Organocatalysts for Enantioselective Holoaminocyclization 
 
In addition to the bifunctional amino-thiocarbamate catalyst, it was later 
discovered that dialkyl cyclic selenide (1.29, Figure 1.4) was also capable 
chiral catalyst for the enantioselective bromoaminocyclization of olefinic 
amides
35
. Building up from d-mannitol, cyclic selenide catalyst was capable of 
affecting the enantioselective cyclization of tri-substituted olefinic amides. 
Interestingly, in contrast to the cinchona alkaloid based amino-thiocarbamates, 




Our laboratory also discovered a range of catalyst-free NBS-initiated 
multicomponent reactions that involved nitrogen as the nucleophile (Scheme 
1.8). In addition to using cyclic ethers, nitriles and cyanimides could be used 
in place to afford a range of imidazoline
36
 (1.30) and guanidine
37
 (1.31), 
respectively. The MCRs proceeds via the one-pot assembly of olefin, NBS, 
NsNH2, and nitriles or cyanimides to afford the respective bromoamides. 
Subsequent intramolecular displacement of the bromides in the bromoamides 
and cyclization (either in-situ or by further refluxing the bromoamides) led to 
the formation of imidazolines and guanidines. 
 
Scheme 1.8 NBS Initiated MCR in the Synthesis of Imidazolines and 
Guanidines 
 
1.1.3 Carbon as nucleophile 
Remarkable progress has been made in recent years on halonium ion induced 
polyene cyclizations. In 2007, Ishihara and co-workers reported the 
enantioselective iodocyclization of polyprenoids
38
 (Scheme 1.9). In their study, 
a stoichiometric amount of the binol-based phosphoramidite (1.32) was used 
as the promoter. The authors proposed that the Lewis basic (1.32) could 
activate NIS to generate an electrophilic iodine source. The electrophilic 
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iodocyclization of the polyprenoid would lead to the trans-fused ring mixture, 
which was then treated with ClSO3H in i-PrNO2 to give the desired 
iodopolycycles. 
 
Scheme 1.9 Phosphoramidite-promoted iodocarbocyclization 
 
A powerful brominating reagent BDSB (1.33) was reported by S. A. Snyder 
and co-workers
39
 which enabled direct formation of cation- cyclization with 
a variety of geraniol, farnesol, and nerol derivatives.  The reagent worked even 
for electron deficient terpenes (Scheme 1.10).  
 
Scheme 1.10 Direct BDSB Induced Polyene Cyclizations  
 
By constructing an enantiopure bromonium ion precursor, such as 1.34, D. C. 
Braddock and co-workers reported their strategy to initiate polyene cyclization 






Scheme 1.11 Enantiospeciﬁc Bromonium Ion Generation and 
Intramolecular Capture 
 
As can be seen from the discussion, cohalogenation reactions are extensively 
utilized in modern organic synthesis. Despite of the significant advances 
achieved in the area of organocatalytic asymmetric halocyclizations, much 
work remains underexplored and requires the efforts from organic chemists. In 
the following sections, cohalogenation reactions involving cyclic ethers and 
aziridines will be reviewed.  
 
1.2 Recent Advances in Halonium Ion Induced Cyclic Ether Ring 
Expansion/Opening Reaction 
 
Although halonium ion induced cyclic ether ring opening reaction was a 
transformation discovered long ago, it is only recently that this strategy was 
widely applied in the total synthesis of natural product.  
 
One of the pioneering work came from H. Fujioka group, who reported an 
halonium ion induced chiral acetal ring expansion cascade reaction (Scheme 
1.12)
41
. In his paper, chiral hydrobenzoin protected ene acetal 1.35 was 
designed as the substrate for electrophilic activation by halonium ion. The 
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following attack of one of the acetal oxygen atoms forms the bicyclic oxonium 
ion intermediate 1.36. In the presence of other nucleophiles, such as 2-
methoxyethanol, ring expansion product (1.37) could be formed in good 
stereoselectivity due to the rigid conformation of the bicyclic intermediate. 
Iodination reagent I(coll)2ClO4 (iodonium di-sym-collidine perchlorate) 
provided better stereoselectivity than other halogenation reagent in this case.  
 
Scheme 1.12 Intramolecular Iodoetherification Reaction of Chiral Ene 
Acetals 
 
After substitution of the iodide by the nucleophile, the alkoxy group of the 
mixed acetal was then converted to an alkyl group by Grignard substitution. 
The final removal of the chiral auxiliary unit using catalytic hydrogenolysis or 
Birch reduction proceeded smoothly and successfully afforded the 
corresponding optically active 1,4-diols (1.38), which is an important building 
block for complex molecule synthesis (Scheme 1. 13). 
 
Scheme 1.13 Transformation to Optically Active 1,4-Diols 
 
This strategy was later on applied in the total synthesis of several natural 
products (Figure 1.5), including  (+)-Rubrenolide 
42









Figure 1.5 Natural Product Synthesized Using Halonium Ion Induced 
Chiral Acetal Ring Expansion Cascade Reaction 
 
While exploring Lewis acid promoted polyepoxide oxacyclization reactions, F. 
E. McDonald group discovered that Br(coll)2ClO4 (bromonium di-sym-
collidine perchlorate) could also induce endo-regioselective cyclization of 
epoxyalkene 1.42 to afford predominantly bromooxepanes 1.43 and 1.44  as a 
separable mixture of diastereomers
45
 (Scheme 1.14). 
 
Scheme 1.14 endo,endo-Bromocyclization of Epoxyalkene 1.42 
 
In 2009, the ﬁrst example of a bromonium-initiated multiepoxide cascade was 
reported by T. F. Jamison’s group in their total synthesis of ent-
Dioxepandehydrothyrsiferol 1.47 , which bears the trans-anti-trans fused 
tricyclic subunit
46
. The triepoxide fragment 1.45 was constructed by Sharpless 
asymmetric epoxidation and Shi epoxidation. Upon treatment of 1.45 with 
NBS in HFIP, the cascade proceeded with the predicted regioselectivity in the 
bromonium-opening and all epoxide-opening events, furnishing a 72% 
combined yield (90% perepoxide) of a 1:1 mixture of the desired product 
(1.46) and a diastereomer resulting from unselective bromonium formation 
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(Scheme 1.15). After fragment coupling, the total synthesis was completed in 
five more steps. 
 
Scheme 1.15 Total Synthesis of ent-Dioxepandehydrothyrsiferol via a 
Bromonium-Initiated Epoxide-Opening Cascade 
 
D. C. Braddock contributed greatly in this field. In 2006, he proposed the 
biosynthesis of Obtusallene family starting from 1.48 that resulted from 
nucleophilic ring opening of (Z)-6,7-epoxide with chloride anion
47
. 
Subsequent bromonium ion activation of C9-C10 olefin followed by a 5-exo 
bromoetherification gives the tetrahydrofuran 1.49. The second electrophilic 
bromination at C12-C13lead to an oxonium ion intermediate 1.50, which can 
fragment to 1.51. The third delivery of electrophilic bromine to enyne allows 
for a macrobromoetherification affording Obtusallene II (1.52) and IV (1.53). 
Furthermore, the author proposed that Obtusallene II is the biosynthetic 
precursor of all the remaining Obtusallenes via a common fourth bromonium 




Scheme 1.16 Proposed Biosynthesis of Obtusallene Family via 
Electrophilic Bromination 
 
Although a reasonable hypothesis, this multiple electrophilic bromination 
process has to be supported by experimental results. One of the key steps of 
transforming Obtusallenes II (1.52) to other Obtusallenes: bromonium ion 
induced oxonium ion formation - fragmentation was demonstrated in a model  
Obtusallene system
48
(Scheme 1.17). In this report, the 11-membered strained 
macrocycle 1.54 corresponding to Obtusallene II was prepared by ring-closing 
metathesis. Its treatment of NBS gave macrocyclic carbon frameworks (1.56) 
corresponding to obtusallene VII, which resulted from nucleophilic attack of 
C-6 of oxonium ion intermediate (1.55). The nucleophilic attack of C-9 led to 
an additional brominated [5,5,1]bicyclotridecane product(1.57), suggesting 
that it represented the core of an undiscovered natural product. As a matter of 






Scheme 1.17 Bromonium Ion Induced Oxonium Ion Formation - 
Fragmentation Using NBS 
 
The using of epoxides was also explored by Braddock’s group. In 2011, he 
reported the first examples of intramolecular bromonium ion assisted epoxide 
ring-expansions with trapping of the presumed resultant oxonium ion by added 
external nucleophiles, such as carboxylic acid, alcohol, water, and halide
50
. 9-
Oxabicyclo[6.1.0]non-4-ene (1.58) was selected as substrate and NBS was 
used as the bromine source. An active oxonium ion intermediate (1.59) formed 
after the electrophilic activation of the double bond by NBS. The external 
nucleophiles favored the nucleophilic attack of the epoxide ring at high 
dilution instead of direct ring opening of the bromonium ion.  However, the 
reaction still suffers from low regioselectivity of the nucleophilic capture on 




Scheme 1.18 Intramolecular Bromonium Ion Assisted Epoxide Ring-
Opening 
 
Furthermore, this strategy was explored in the total synthesis of natural 
products. A linear model epoxide 1.60 was constructed for the feasibility of an 
intramolecular bromonium ion assisted epoxide ring-opening reaction. Using 
Snyder ’s powerful BDSB reagent39, six medium-ring ether products 
concurrently formed (Scheme 1.19), which correlate to several medium-ring 





Scheme 1.19 Model Epoxide Study on Intramolecular Bromonium Ion 
Assisted Epoxide Ring-Opening 
 
In 2011, S.A. Snyder et al. demonstrated their strategy for the stereocontrolled 
preparation of diverse medium-ring Laurencia-type bromothers
52
. In his 
transformation, model compound 1.61 was designed to represent the first 
bromoetherification product from its linear precursor. The bromonium ion (1. 
62) was delivered by the novel brominating reagent BDSB, which has been 
proved the most efficient compared with other bromonium sources
39
.  The 
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tetrahydrofuran ring would then act as nucleophile to open the three-
membered bromonium ion leading to a bicyclic oxonium intermediate (1.63 ), 
the nucleophilic attack of which could provide the ring expansion product 
(1.64 ) resembling those of the Laurencia acetogenins (Scheme 1.20). 
 
Scheme 1.20 Bromonium Ion Induced Oxonium Ring Expansion to 
Laurencia Acetogenins 
 
This strategy was then successfully utilized to the total synthesis of some of 
the natural products from Laurencia family
53
. As the key precursor for the 
BDSB-induced oxonium ring-expansion reaction, the tetrahydrofuran 
substrates (1.65) need to be carefully forged so that they possess a strategically 
positioned exocyclic alkene, an internal nucleophilic trap, and properly 
designed side chain that could be transferred to enyne. Its treatment with 1.5 
equiv of BDSB in MeNO2 afforded the bromoether (1.67) in 72 % yield in a 
single stereoisomer. Probably due to the facile bromonium ion transfer and 
reversible oxonium formation, only the less sterically hindered oxonium 
intermediate (1.66) is capable of leading to product. Exposure of the ring 
expansion product to DIBAL-H gave the bridging tetrahydrofuan ring product 
(1.68), which could be converted to the (±)-Laurefucin (1.69) in two more 




Scheme 1.21 Concise Synthesis of (±)-Laurefucin 
 
Applying basically the same strategy and with carefully forged 
tetrahydrofuran substrates, (±)-E- and ( ± )-Z-pinnatiﬁdenyne were also 
synthesized in 14 steps stereoselectively.  
 
Scheme 1.22 NBS-Mediated Oxetane Ring Expansion 
 
Oxetane also proved to be a good nucleophile to attack the bromonium ion. In 
2012, A. R. Howell group reported the discovery while attempting to 
synthesize Laureatin
54
. Alkenol (1.70) was prepared for NBS activation, 
instead of forming the desired bicyclic system (1.71), epoxytetrahydrofuran 
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(1.72) was isolated as a single diastereomer in 51% yield (Scheme 1.22). The 
unexpected formation was explained by reaction of the oxetane moiety, rather 
than the alcohol, with the initially formed bromonium ion.  
 
1.3 Recent Advances in Bromonium Ion Induced Aziridine Ring 
Expansion Reaction 
 
Despite the extensive research on bromonium ion induced cyclic ether ring 
opening/expansion reactions and synthetic applications (as presented in 
section 1.2), bromonium ion induced aziridine ring opening/expansion 
reactions are rarely reported. In this section, historical research on bromonium 
ion induced aziridine ring expansion related reactions will be reviewed. 
 
Aziridines, the nitrogenous analogues of epoxides, have received far less 
interest among organic chemists than their oxygenated counterparts. Due to 
the diminished electronegativity of nitrogen compared with oxygen, ring 
opening reactions of aziridines are less facile than the corresponding reactions 
of epoxides.
55
  Probably because of their decreased reactivity, aziridines are 
rarely used in complex molecule synthesis. The fact that the protection and 
deprotection of the nitrogen in aziridines require rigid operation due to their 
instability toward acidic reagents has worsened the situation.
56
 Even though 
the halogen activation of carbon-carbon double bond followed by nucleophilic 
attack of aziridine might be a novel pathway for the construction of unique 




In 2006, Kimpe group reported their discovery of a novel diastereoselective 
transformation of 1-tert-butyl-2-(allyloxymethyl)aziridine (1.73) into cis-3,5-
di(bromomethyl)-4-tert-butylmorpholine (1.75), which was performed in 
dichloromethane using bromine as electrophilic initiator (Scheme 1.23)
57
. 
Activation of the double bond was achieved by the addition of 1.05 equiv of 
bromine in dichloromethane to afford the morpholine product as one 
stereoisomer in 88% crude yield (43% after column chromatography). The 
relative cis- stereochemistry was confirmed by X-ray analysis of the single 
crystal of the product. 
 
Scheme 1.23 Novel Synthesis of cis-3,5-Disubstituted Morpholine 
 
The authors proposed that the reaction proceeded from electrophilic addition 
of bromine to the double bond, forming bromonium ion, which is a typical 
intermediate in similar circumstances. The aziridine would then act as 
nucleophile to open the bromonium ring, forming the bicyclic aziridinium 
intermediate (1.74), which would take the more stable chair like conformation. 
anti-Markovnikov ring opening of the aziridinium moiety by bromide at the 
unsubstituted aziridine carbon atom then would give the cis-3,5-disubstituted 
morpholine.  
 
The morpholine obtained was used as a substrate for the preparation of the 
corresponding 3,5-di(methoxymethyl)morpholine (1.76, Scheme 1.24) and 
3,5-di(cyanomethyl)morpholine (1.77, Scheme 1.24) upon nucleophilic 
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displacement of both bromo atoms. However, Due to the fact that only 
dibrominated meso-morpholine was formed, which makes this reaction 
unpractical to be applied into the preparation of chiral morpholine compound 
and limits the synthetic applications.  
 
Scheme 1.24 Transformation of Dibrominated meso-Morpholine 
 
The authors also pointed out that tertiary butyl group substitution on nitrogen 
of the aziridine ring was crucial for the transformation. N-neopentyl 
substitution gave the second to the best yield 40%. It was claimed that other 
substitutions would lead to morpholine product decomposition on silica gel. 
This limitation not only constrained the substrate scope of the reaction, but 
also made the preparation of substrates challenging. 
 
A related cycloamination reaction was reported by A. K. Yudin in 2003 (Table 
1.1). 
58
 The starting building block containing aziridine separated by a (CH2)2 
linker from the olefin was prepared from commercially available materials in 
five steps.
59
  The treatment of the terminal olefinic aziridines (1.78) with N-
bromosuccinimide (NBS) in DME/water allowed for conversion into 1-
azabicyclo[3.1.0]hexane derivatives (1.79 and 1.80) in good yields (Table 1.1 , 
entry 1 – 3, 5), Whereas aryl-substituted double bonds preferentially give six-




The authors proposed that the reaction of NH aziridine with NBS would 
immediately lead to the active bromoamine (N-Br) intermediate, which would 
in turn activate olefin to give bromonium ion. The bromonium ion was then 
attacked by the aziridine counterpart leading to cycloamination product. 
Although without direct and solid evidence of the presence of N-Br 
intermediate, by reaction of the starting material with N-chlorosuccinimide 
(NCS), the authors successfully prepared similar chloroamine (N-Cl) species 
which was stable enough for identification.  
 
Table 1.1 Yudin’s Intramolecular Aminocyclization of Olefins 
 
entry R1 R2 Product yield 
1 H PhCO 1.79a 76 
2 Me PhCO 1.79b 51 
3 CH2OH PhCO 1.79c 54 
4 Ph PhCO 1.80 67 
5 H PhCH(OH) 1.79d 55 
 
The resulting bicyclic products (1.79), an important class of targets for 
stereoslective synthesis, were utilized to transfer to a series of enamines (1.81) 
by dehydrobromination.  The enamines obtained could be further manipulated 
to give pyrolidine derivatives (1.82) upon ring opening reaction. The resulting 







Table 1.2 Synthetic Application of 1-Azabicyclo[3.1.0]hexane Derivatives 
 
entry R1 condition R2 yield (%) 
1 H TMSN3 2eq, H2O 10eq, DCM, r.t. N3 99 
2 Me TMSN3 2eq, H2O 10eq, DCM, r.t. N3 95 
3 H HBF4 1.5eq, MeOH, r.t. OMe 65 
4 H AcOH 5eq, DCM, r.t. OAc 73 
5 H 10% Pd/C, H2 H 99 
 
Although an innovative work represents the first example of bromonium ion 
induced aziridine cyclization, the report still suffers from several inadequacies: 
firstly, the author did not point out whether the reaction applied only to 
aziridines bearing electron withdrawing groups; secondly, according to the 
mechanistic study, the reaction worked only when there were no protecting 
groups for the nitrogen of aziridines, while these kinds of aziridines were 
unstable and difficult to synthesize; apart from these, the stereoselectivities of 
the reactions were barely satisfactory. The diastereomeric ratios were as 
follows: for 1.79a, 41:59; for 1.79b, 33:67; for 1.79c, 33:67, for 1.80, an 
improved ratio was observed 19:81, but with 23 % of regioisomer. Thus, a 
highly stereoselective reaction with versatile aziridine substrates becomes 
highly attractive.   
 
1.4 Aim of the study 
 
Due to its significant utility to construct complex molecules with diverse 
functional groups and to create carbon-heteroatom bond, cohalogenation 
reactions are potent in the synthesis of various natural products and drug-like 
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molecules. As can be seen from the previous sections, its multicomponent 
version is still at its early stage of development. Our interest in carbon-halogen 
bond formation prompts us to further investigate bromonium ion induced 
epoxide ring opening and aziridine ring expansion reactions. 
1.4.1 Bromonium ion induced epoxide ring opening 
Bromonium ion induced cyclic ether ring opening reactions have recently been 
successfully applied in the total synthesis of some natural products. However, 
without any exception the substrates need to be carefully designed so as to 
obtain high stereoselectivity.  In this thesis, we would like to extend the 
bromonium ion induced oxonium ring opening reactions into epoxide 
substrates, which are easier to prepare and more widely used in organic 
synthesis. Apart from that, we would also like to apply the method to the 
synthesis of bioactive morpholine compounds, and even drug molecules.  
1.4.2 Bromonium ion induced aziridine ring expansion 
As described in section 1.3, bromonium ion induced aziridine ring expansion 
reactions were rarely reported, which demands more efforts from organic 
chemists. 
The research gaps are summarized below: 
 The substrate scope of bromonium ion induced aziridine reactions was 
extremely limited, partly due to the vague reaction mechanism and the 
instability of inactivated aziridine; 
 Stereoselectivity of such reactions was far from satisfactory; 
 The reaction mechanism was never studied. 
The main aim of research is was to: 
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 provide a novel multicomponent bromonium ion induced aziridine ring 
expansion reaction with high stereoselectivity; 
 investigate the scope of such reaction; 
 propose a reliable reaction mechanism; 
 apply the reaction into the synthesis of bioactive compounds. 
The result of both studies should have significant impact on both giving new 
insight into the area of multicomponent electrophilic cohalogenation reactions 
and providing preparation method of bioactive molecules. 
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Chapter 2  
Bromonium Ion Induced Epoxide Ring 






The increasing demand for new chemical entities urges synthetic chemists to 
pursue simple, efficient, selective, high yielding, and environmentally benign 
reactions.
1
 Multicomponent reactions (MCR), which allow the quick assembly 
of several simple reactants into complex structures in one pot, certainly 
provide a possible solution for a green and efficient synthesis through a 
diversity-oriented approach.
2
 These one-pot processes are highly efficient to 
construct the scaffold of natural products and diverse drug-like molecules 





Among MCRs, electrophilic MCRs were less reported, partly due to the 
common incompatibility of electrophiles with other components.
4
 
Nevertheless, recently, we reported our discovery of electrophilic 
aminoalkoxylation reactions
5
 (Scheme 2.1). 
 
Scheme 2.1 Multicomponent Electrophilic Aminoalkoxylation Reaction 
 
The scope of the aminoalkoxylation was quite broad in regard to both the 
oleﬁnic component (Table 2.1) and the cyclic ether partner (Table 2.2).  
 
As an extension of this discovery, the application of epoxides in the reaction 
system was further investigated. However, a challenging task was encountered 
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during the process development: when a mono-substituted epoxide was used, 
the oxonium intermediate could be opened through the anti-Markovnikov 
(path A) or the Markovnikov (path B) pathway (Scheme 2.2). 
Table 2.1 Synthesis of Amino Ethers Using Various Oleﬁns 
 
 




Scheme 2.2 Aminoalkoxylation Using Monosubstituted Epoxide 
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Product A, the anti-Markovnikov product, is a privileged building block for 2- 
and 6-substituted morpholines. In particular, 2,2,6-trisubstituted morpholine A' 
is an important pharmacophore (Figure 2.1).
6
 Common strategies, such as the 
cyclization of amino alcohols (derived from amino acids which contain -
nitrogen substituents), can readily achieve 3-substituted morpholine B'.
7
 In 
comparison, it is not trivial to achieve A' or related compounds, particularly 




Figure 2.1 Examples of Bioactive Morpholines 
 
In the following section, an unexpected finding on the formation of the anti-
Markovnikov product A when using epichlorohydrin as the partner in the 
aminoalkoxylation MCR was presented. Subsequent application to the 
synthesis of 2,2,6-trisubstituted morpholine A' is also described. 
 




The investigation was initiated by studying a number of mono-substituted 
epoxides using cyclohexene as the model substrate. Propylene oxide gave no 
selectivity regardless of the high reaction yield (Table 2.3, entry 1). 1,2-
Epoxy-3-methylbutane gave a better regioselectivity, presumably due the 
steric hindrance which suppressed the path B nucleophilic attack (Table 2.3, 
entry 2). Other alkoxy/siloxy systems were also examined, and some 
regioselectivities were observed; up to a 2.5:1 ratio but a relatively low 
conversion (56% yield) was detected when using the bulky OTBDPS-
substituted epoxide (Table 2.3, entries 3–5). Such steric effect was not 
significant, which might be attributed to the electron-donating ability of the 
substituents that favored the Markovnikov-type product 2-3a.  





 Reactions were carried out with cyclohexene (2-1a) (0.24 mmol), NsNH2 (0.2 
mmol), and NXS (0.24 mmol) in epoxide (0.4 mL). 
b
 Isolated yield; 
c
 Based on 
NMR analysis of crude product. 
d
 N-chlorosuccinimide was used. 
e
 N-
iodosuccinimide was used. 
Interestingly, the electron-deficient epoxides, epibromohydrin and 
epichlorohydrin, gave good chemical yields and regioselectivity (Table 2.3, 
entries 6 and 7). Optimization of the reaction temperature led us to achieve an 
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8:1 ratio of regioselectivity at –30 oC (Table 2.3, entry 9). Other halogen 
sources were investigated. The reaction was sluggish when using N-
chlorosuccinimide (NCS) (Table 2.3, entry 11). Although a better 
regioselectivity was observed when using N-iodosuccinimide (NIS), the 
chemical conversion was only moderate (Table 2.3, entry 12). 
Table 2.4 Aminoalkoxylation of Olefin 2-1 
 
a
 Reactions were carried out with NsNH2 (0.2 mmol), olefin 2-1 (0.24 
mmol),and NBS (0.24 mmol) in epichlorohydrin (0.4 mL) at –30 oC for 16 h. b 
Isolated yield of the mixture of 2-2 and 2-3 by column chromatography; 
c
 Based 




Having identified a suitable system, some 1,1-disubstituted olefins were 
examined. A number of exocyclic olefins gave the desired products with good 
regioselectivities and yields (Table 2.4, entries 1–3). The 4-O-substituted 
cyclohexyl systems including 2-1e and 2-1f also worked well in the reactions 
(Table 2.4, entries 4 and 5). The protected piperidine substrate 2-1g gave the 
corresponding product in 92% yield with a 6:1 ratio of regioselectivity (Table 
2.4, entry 6). This type of MCR reaction worked equally smooth for aliphatic 
1,1-disubstituted olefins, but the reaction rate was somewhat deteriorated 
when using bulkier substrates (Table 2.4, entries 7–10). The stereochemical 
relationship of 2-2 was established by X-ray crystallographic study of 2-2d 
(Figure 2.2). 
 
Figure 2.2 X-ray Structure of 2-2d 
 
After performing the aminoalkoxylation, we were interested to further 
manipulate product 2-2 to achieve the morpholine compounds. In all cases, 
treatment of 2-2 with base in MeCN at room temperature gave the 
corresponding morpholine products exclusively and no chlorine substitution 
(i.e. the four-member ring formation) was observed (Table 2.5). The structures 









 Reactions were carried out with 2-2 (0.1 mmol) and K2CO3 (0.2 mmol) 








Figure 2.3 X-ray Structure of 2-4d 
 
In fact, the reaction can be conducted in a one-pot fashion. For instance, after 
the standard aminoalkoxylation MCR of 2-1f under standard conditions, the 
unused epichlorohydrin was recovered using distillation. The crude mixture 
was then treated with potassium carbonate in MeCN to give the desired 
morpholine 2-4f (Scheme 2.3).  
 
Next, the use of enantiopure (R)-epichlorohydrin was examined in the reaction 
using 2-1f, and the desired morpholine 2-4f was obtained with equal 
magnitude of enantiomeric excess (99% ee). The stereochemistry of 2-4f was 
established by an X-ray crystallographic study. It is noteworthy that 2-4f was 
isolated exclusively as a single enantiomer; that is, the meso-substrate 2-1f, 
which contains a 4-substituted unit, was desymmetrized in the reaction 
(Scheme 2.3).  
Scheme 2.3 One-pot Synthesis of 2-4f 
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For this type of MCR, it was surprising to observe that the electron-deficient 
epoxide epichlorohydrin gave similar reactivity to the corresponding alkyl or 
alkoxy/siloxy epoxides (Table 2.3). We have performed the MCR using an 
electron-deficient OMs epoxide which returned with no reaction (Scheme 2.4, 
eq. 1). A pre-opening of the epoxide in the MCR proved to be unlikely to 
happen (Scheme 2.4, eq. 2). We suspect that the chlorine atom may play a role 
in the reaction; this remains unclear and is subjected to more intensive 
clarification.  
 
Scheme 2.4 Mechanistic Investigation on the MCR 
 
2.3 Summary and Conclusion 
 
In summary, an efficient electrophilic multicomponent reaction was developed 
using epichlorohydrin, an olefin, nosyl amide, and N-bromosuccinimide, 
giving the halogenated products with high regioselectivity. 2,2,6-trisubstituted 
morpholines were achieved by using this protocol. The morpholines contained 
methylene chloride handles that can readily be derivatized to yield other 
functional molecules. When enantiopure epichlorohydrin was used, the 
corresponding optical pure morpholine was accomplished. Interestingly, it was 




2.4 Experimental Section 
 
2.4.1 Materials and general methods 
All reactions that required anhydrous conditions were carried by standard 
procedures under nitrogen atmosphere. Commercially available reagents and 
solvents were used without further treatment. Olefin substrates (Table 2.2) 
were prepared according to literature procedure.
9
 Thin-layer chromatography 
(TLC) was performed with Merck silica gel 60 F254 precoated plates. Merck 
60 (0.040-0.063 mm) mesh silica gel was used for flash chromatography. 





C NMR spectra were recorded on a Bruker AMX 500 (500 MHz and 
125 MHz, respectively) or DRX 500 (500 MHz and 125 MHz, respectively). 
Data for 
1
H NMR spectra are reported as follows: chemical shift ppm 
(multiplicity, coupling constant (Hz), integration). Data for 
1
H NMR spectra 
are referenced to the centerline of CDCl3 7.26) as the internal standard. 
Data for 
13
C NMR spectra are referenced to the centerline of CDCl3 ( 77.0). 
Infrared spectra were recorded on a BIO-RAD FTS 165 FT-IR 
spectrophotometer and reported in frequency of absorption (cm
-1
). High 
resolution mass spectra were obtained on a Finnigan/MAT 95XL-T 
spectrometer in ESI or EI mode. Optical rotations were measured on a Jasco 
DIP-1000 polarimeter using a 10 mm path-length cell at 589 nm. Analytical 
chiral HPLC was performed with a Shimadzu utilizing a Daicel Chiralpak IA 




2.4.2 Aminoalkoxylation of olefin in epichlorohydrin 
 
General procedure for electrophilic aminoalkoxylation in epichlorohydrin: 
To a solution of N-bromosuccinimide (43 mg, 0.24 mmol) and nosyl amide 
(40mg, 0.2 mmol) in epichlorohydrin (0.4 mL) in dark was added olefin 2-1 
(0.24 mmol) at -30 
o
C. After stirring for 16 h at this temperature, the reaction 
was quenched with saturated Na2S2O3 (2 mL). The mixture was extracted with 
EtOAc (3 × 10 mL). The combined extracts were washed with brine (15 mL), 
dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue 





nitrobenzenesulfonamide (2-2b): Synthesized according to the general 
procedure and purified by flash chromatography (hexanes/EtOAc = 8:1) to 




H NMR (500 MHz, CDCl3) 
δ 8.37 (d, J = 8.9 Hz, 2H), 8.07 (d, J = 8.9 Hz, 2H), 5.17 (m, 1H), 3.78 (m, 
1H), 3.48 (m, 3H), 3.40 (d, J = 11.4 Hz, 1H), 3.33 (m, 1H), 3.23 (m, 1H), 
1.88~1.61 (m, 8H) ppm; 
13
C NMR (125 MHz, CDCl3) δ 150.41, 145.75, 
128.64, 124.62, 88.41, 71.63, 44.97, 43.76, 40.38, 37.83, 35.20, 24.67, 23.89 
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ppm; IR (KBr): 2960, 1531, 1349, 1165, 1093 cm
-1
; HRMS (ESI) calcd for 
C15H19BrClN2O5S [M-1]
-




nitrobenzenesulfonamide (2-2c): Synthesized according to the general 
procedure and purified by flash chromatography (hexanes/EtOAc = 8:1) to 




H NMR (500 MHz, CDCl3) 
δ 8.37 (d, J = 8.7 Hz, 2H), 8.07 (d, J = 8.7 Hz, 2H), 5.15 (m, 1H), 3.90 (m, 
1H), 3.49 (m, 4H), 3.36 (m, 1H), 3.20 (m, 1H), 1.65~1.34 (m, 10H) ppm; 
13
C 
NMR (125 MHz, CDCl3) δ 150.18, 145.56, 128.44, 124.39, 77.15, 69.29, 
44.73, 43.60, 39.92, 34.70, 33.15, 25.17, 22.83, 22.53 ppm; IR (KBr): 2925, 
1531, 1350, 1166, 1061 cm
-1
; HRMS (ESI) calcd for C16H21BrClN2O5S [M-1]
-
: 




nitrobenzenesulfonamide (2-2d): Synthesized according to the general 
procedure and purified by flash chromatography (hexanes/EtOAc = 8:1) to 




H NMR (500 MHz, CDCl3) 
δ 8.37 (d, J = 8.8 Hz, 2H), 8.07 (d, J = 8.8 Hz, 2H), 5.15 (m, 1H), 3.87 (m, 
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1H), 3.52 (dd, J = 4.2, 11.3 Hz, 1H), 3.46 (dd, J = 8.4, 11.2 Hz, 1H), 3.39 (m, 
2H), 3.34 (m, 1H), 3.21 (m, 1H), 1.81 (m, 2H), 1.70 (m, 2H), 1.56 (m, 6H), 
1.37 (m, 2H) ppm; 
13
C NMR (125 MHz, CDCl3) δ 150.20, 145.60, 128.44, 
124.39, 81.16, 69.70, 44.76, 43.64, 41.63, 37.89, 36.18, 30.16, 30.03, 22.89, 
22.52 ppm; IR (KBr): 2927, 1526, 1345, 1168, 1062 cm
-1
; HRMS (ESI) calcd 
for C17H23BrClN2O5S [M-1]
-




chloropropyl)-4-nitrobenzenesulfonamide (2-2e): Synthesized according to 
the general procedure and purified by flash chromatography (hexanes/EtOAc 




H NMR (500 
MHz, CDCl3) δ 8.36 (d, J = 8.6 Hz, 2H), 8.07 (d, J = 8.6 Hz, 2H), 5.23 (m, 
1H), 3.89 (m, 1H), 3.74 (m, 1H), 3.51 (m, 3H), 3.36 (m, 2H), 3.21 (m, 1H), 
1.97 (m, 2H), 1.52 (m, 6H), 0.88 (s, 9H), 0.04 (s, 6H) ppm; 
13
C NMR (125 
MHz, CDCl3) δ 150.19, 145.64, 128.43, 124.37, 76.56, 69.65, 67.11, 44.82, 
43.56, 39.62, 31.04, 30.87, 30.41, 28.61, 25.80, 18.06, -4.79 ppm; IR (KBr): 
2951, 1532, 1349, 1167, 1093 cm
-1
; HRMS (ESI) calcd for 
C22H35BrClN2O6SSi [M-1]
-






nitrobenzenesulfonamide (2-2f): Synthesized according to the general 
procedure and purified by flash chromatography (hexanes/EtOAc = 5:1) to 




H NMR (500 MHz, 
CDCl3) δ 8.37 (d, J = 8.7 Hz, 2H), 8.08 (d, J = 8.7 Hz, 2H), 5.16 (m, 1H), 4.75 
(m, 1H), 3.90 (m, 1H), 3.56 (m, 2H), 3.46 (d, J = 11.8 Hz, 1H), 3.41 (m, 1H), 
3.36 (d, J = 11.8 Hz, 1H), 3.22 (m, 1H), 2.06 (s, 3H), 1.94 (m, 2H), 1.71 (m, 
2H), 1.56 (m, 4H) ppm; 
13
C NMR (125 MHz, CDCl3) δ 170.42, 150.22, 
145.47, 128.44, 124.42, 75.93, 70.11, 69.84, 44.55, 43.58, 39.28, 31.68, 29.76, 
27.18, 26.80, 21.28 ppm; IR (KBr): 2952, 1726, 1530, 1350, 1256, 1166, 1063 
cm
-1
; HRMS (ESI) calcd for C18H23BrClN2O7S [M-1]
-





nitrophenylsulfonamido)propan-2-yloxy)piperidine -1-carboxylate (2-2g): 
Synthesized according to the general procedure and purified by flash 
chromatography (hexanes/EtOAc = 8:1) to afford a clear oil (yield: 92 %). 
1
H 
NMR (500 MHz, CDCl3) δ 8.38 (d, J = 8.7 Hz, 2H), 8.07 (d, J = 8.7 Hz, 2H), 
5.11 (m, 1H), 3.93 (m, 1H), 3.60~3.47 (m, 5H), 3.41 (m, 2H), 3.32 (m, 2H), 
3.21 (m, 1H), 1.81 (m, 2H), 1.62 (m, 2H), 1.45 (s, 9H) ppm; 
13
C NMR (125 
MHz, CDCl3) δ 154.44, 150.20, 145.34, 128.41, 124.47, 80.12, 75.53, 69.89, 





; HRMS (ESI) calcd for C20H28BrClN3O7S [M-1]
-





nitrobenzenesulfonamide (2-2h): Synthesized according to the general 
procedure and purified by flash chromatography (hexanes/EtOAc = 8:1) to 




H NMR (500 MHz, 
CDCl3) δ 8.37 (d, J = 8.9 Hz, 2H), 8.07 (d, J = 8.9 Hz, 2H), 5.20 (m, 1H), 3.92 
(m, 1H), 3.51 (dd, J = 3.9, 11.2 Hz, 1H), 3.45 (dd, J = 8.4, 11.2 Hz, 1H), 3.40 
(d, J = 11.5 Hz, 1H), 3.34 (m, 2H), 3.20 (m, 1H), 1.59 (m, 4H), 0.84 (m, 6H) 
ppm; 
13
C NMR (125 MHz, CDCl
3) δ 150.11, 145.48, 128.41, 124.39, 80.56, 
69.36, 44.66, 43.41, 38.82, 27.34, 26.62, 8.35, 7.63 ppm; IR (KBr): 2973, 
1531, 1350, 1167, 1077 cm
-1
; HRMS (ESI) calcd for C15H21BrClN2O5S [M-1]
-
: 




nitrobenzenesulfonamide (2-2i): Synthesized according to the general 
procedure and purified by flash chromatography (hexanes/EtOAc = 8:1) to 




H NMR (500 MHz, 
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CDCl3) δ 8.37 (d, J = 8.8 Hz, 2H), 8.07 (d, J = 8.8 Hz, 2H), 5.18 (m, 1H), 3.92 
(m, 1H), 3.50~3.32 (m, 5H), 3.18 (m, 1H), 1.51 (m, 4H), 1.23 (m, 4H), 0.91(m, 
6H) ppm; 
13
C NMR (125 MHz, CDCl3) δ 150.12, 145.49, 128.42, 124.39, 
80.06, 69.31, 44.70, 43.47, 39.63, 37.64, 36.83, 17.37, 16.59, 14.43, 14.32 
ppm; IR (KBr): 2957, 1531, 1347, 1166, 1087 cm
-1
; HRMS (ESI) calcd for 
C17H25BrClN2O5S [M-1]
-




nitrobenzenesulfonamide (2-2j): Synthesized according to the general 
procedure and purified by flash chromatography (hexanes/EtOAc = 8:1) to 
afford a clear oil (yield: 43 %). 
1
H NMR (500 MHz, CDCl3) δ 8.31 (d, J = 8.9 
Hz, 2H), 7.88 (d, J = 8.9 Hz, 2H), 7.32 (m, 8H), 7.23 (m, 2H), 4.80 (m, 1H), 
4.18 (m, 1H), 3.53 (m, 2H), 3.36 (m, 1H), 3.30 (m, 2H), 3.14 (d, J = 13.8 Hz, 
1H), 3.01 (m, 3H), 2.91 d, J = 14.0 Hz, 1H) ppm; 
13
C NMR (125 MHz, CDCl3) 
δ 150.02, 145.30, 135.76, 135.52, 130.60, 130.43, 128.60, 128.52, 128.25, 
127.27, 127.20, 124.31, 80.03, 70.27, 44.65, 43.35, 42.53, 41.53, 38.94 ppm; 
IR (neat): 2930, 1531, 1349, 1167, 1079 cm
-1
; HRMS (ESI) calcd for 
C25H25BrClN2O5S [M-1]
-






nitrobenzenesulfonamide (2-2k): Synthesized according to the general 
procedure and purified by flash chromatography (hexanes/EtOAc = 8:1) to 




H NMR (500 MHz, CDCl3) 
δ 8.37 (d, J = 8.8 Hz, 2H), 8.07 (d, J = 8.8 Hz, 2H), 5.01 (m, 1H), 4.33 (m, 
1H), 3.59 (d, J = 11.7 Hz, 1H), 3.55 (d, J = 11.7 Hz, 1H), 3.54 (m, 1H), 3.47 
(dd, J = 8.3, 11.1 Hz, 1H), 3.37 (m, 1H), 3.21 (m, 1H), 2.15 (m, 1H), 2.06 (m, 
1H), 0.99 (m, 12H) ppm; 
13
C NMR (125 MHz, CDCl3) δ 150.20, 145.56, 
128.40, 124.42, 82.83, 69.80, 44.67, 43.62, 36.78, 33.77, 33.36, 18.74, 18.51, 
18.39, 18.25 ppm; IR (KBr): 2931, 1531, 1349, 1167, 1078 cm
-1
; HRMS (ESI) 
calcd for C17H25BrClN2O5S [M-1]
-
: 483.0362, found: 483.0353. 
2.4.3 Base-mediated cyclization 
 
General procedure for the preparation of tri-substituted morpholines: A 
mixture of compound 2-2 (0.1 mmol) and K2CO3 (28 mg, 0.2 mmol) was 
stirred in acetonitrile (2 mL) at 25 
o
C. The reaction was stirred at this 
temperature for 8 h. The solvent was then removed under reduced pressure 
and the residue was purified by flash column chromatography to yield the 





7-(chloromethyl)-9-nosyl-6-oxa-9-azaspiro[4.5]decane (2-4b): Synthesized 
according to the general procedure and purified by flash chromatography 




H NMR (500 MHz, CDCl3) δ 8.41 (d, J = 8.7 Hz, 2H), 7.94 (d, J = 8.7 Hz, 
2H), 3.95 (m, 1H), 3.85 (d, J = 11.1 Hz, 1H), 3.50 (dd, J = 4.6, 11.4 Hz, 1H), 
3.44 (dd, J = 1.1, 11.3 Hz, 1H), 3.35 (dd, J = 6.7, 11.4 Hz, 1H), 2.29 (d, J = 
11.3 Hz, 1H), 2.14 (t, J = 10.8 Hz, 1H), 1.93~1.69 (m, 5H), 1.60 (m, 2H), 1.47 
(m, 1H) ppm; 
13
C NMR (125 MHz, CDCl3) δ 150.36, 141.70, 128.82, 124.49, 
83.88, 69.83, 52.65, 47.98, 44.14, 38.03, 33.24, 24.59, 23.47 ppm; IR (KBr): 
2960, 1531, 1350, 1168, 1090 cm
-1
; HRMS (EI) calcd for C15H19ClN2O5S 
[M]
+




Synthesized according to the general procedure and purified by flash 





H NMR (500 MHz, CDCl3) δ 8.41 (d, J = 8.8 Hz, 2H), 7.94 
(d, J = 8.8 Hz, 2H), 4.03 (m, 1H), 3.86 (dd, J = 1.7, 11.1 Hz, 1H), 3.56 (d, J = 
11.4 Hz, 1H), 3.50 (dd, J = 5.1, 11.3 Hz, 1H), 3.34 (dd, J = 6.5, 11.3 Hz, 1H), 
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2.09 (m, 2H), 1.68~1.31 (m, 10H) ppm; 
13
C NMR (125 MHz, CDCl3) δ 
150.36, 142.05, 128.73, 124.48, 73.02, 67.67, 53.31, 48.31, 44.33, 36.31, 
29.30, 25.81, 21.21, 21.11 ppm; IR (KBr): 2927, 1527, 1348, 1175, 1106 cm
-1
; 
HRMS (EI) calcd for C16H21ClN2O5S [M]
+




Synthesized according to the general procedure and purified by flash 





H NMR (500 MHz, CDCl3) δ 8.41 (d, J = 8.8 Hz, 2H), 7.94 
(d, J = 8.8 Hz, 2H), 3.98 (m, 1H), 3.85 (d, J = 10.9 Hz, 1H), 3.48 (dd, J = 4.9, 
11.4 Hz, 1H), 3.45 (dd, J = 1.5, 11.4 Hz, 1H), 3.32 (dd, J = 6.7, 11.4 Hz, 1H), 
2.08 (t, J = 10.8 Hz, 1H), 2.04 (d, J = 11.4 Hz, 1H), 1.95 (m, 2H), 1.69~1.56 
(m, 5H), 1.49 (m, 2H), 1.37(m, 3H) ppm; 
13
C NMR (125 MHz, CDCl3) δ 
150.32, 141.90, 128.74, 124.49, 76.87, 68.09, 53.36, 47.98, 44.34, 40.22, 
31.45, 29.61, 29.23, 22.00, 21.69 ppm; IR (KBr): 2931, 1528, 1348, 1171, 
1090 cm
-1
; HRMS (EI) calcd for C17H23ClN2O5S [M]
+







azaspiro[5.5]undecane (2-4e): Synthesized according to the general 
procedure and purified by flash chromatography (hexanes/EtOAc = 10:1) to 




H NMR (500 MHz, 
CDCl3) δ 8.41 (d, J = 8.7 Hz, 2H), 7.93 (d, J = 8.7 Hz, 2H), 4.01 (m, 1H), 3.89 
(d, J = 11.1 Hz, 1H), 3.65 (m, 1H), 3.53 (dd, J = 4.5, 11.4 Hz, 1H), 3.46 (d, J 
= 11.4 Hz, 1H), 3.34 (dd, J = 7.0, 11.3 Hz, 1H), 2.33 (d, J = 14.0 Hz, 1H), 
2.12 (m, 2H), 1.69 (m, 1H), 1.61 (m, 3H), 1.48 (m, 1H), 1.39 (m, 1H), 1.30 (m, 
1H), 0.88 (s, 9H), 0.05 (s, 3H), 0.04 (s, 3H) ppm; 
13
C NMR (125 MHz, CDCl3) 
δ 150.39, 141.99, 128.73, 124.50, 72.10, 69.86, 67.69, 53.09, 48.31, 44.17, 
33.56, 30.06, 29.99, 26.45, 25.85, 18.15, -4.64, -4.67 ppm; IR (KBr): 2952, 
1538, 1352, 1171, 1107 cm
-1
; HRMS (EI) calcd for C18H26ClN2O6SSi [M-t-
Bu]
+
: 461.0969, found: 461.0974. 
 
 
2-(chloromethyl)-4-nosyl-1-oxa-4-azaspiro[5.5]undecan-9-yl acetate (2-4f): 
Synthesized according to the general procedure and purified by flash 





H NMR (500 MHz, CDCl3) δ 8.41 (d, J = 8.7 Hz, 2H), 7.93 
(d, J = 8.7 Hz, 2H), 4.73 (m, 1H), 4.00 (m, 1H), 3.87 (d, J = 11.1 Hz, 1H), 
3.51 (dd, J = 5.2, 11.4 Hz, 1H), 3.46 (d, J = 11.8 Hz, 1H), 3.38 (dd, J = 6.4, 
11.4 Hz, 1H), 2.45 (d, J = 14.6 Hz, 1H), 2.14 (m, 2H), 2.04 (s, 3H), 1.77 (m, 
2H), 1.59 (m, 3H), 1.38 (m, 2H) ppm; 
13
C NMR (125 MHz, CDCl3) δ 170.53, 
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150.44, 141.85, 128.76, 124.55, 71.76, 71.66, 67.99, 53.31, 48.23, 44.15, 
33.66, 26.58, 25.83, 25.77, 21.31 ppm; IR (KBr): 2955, 1727, 1530, 1350, 
1261, 1168, 1036 cm
-1
; HRMS (EI) calcd for C12H19ClNO3 [M-Ns]
+
: 




carboxylate (2-4g): Synthesized according to the general procedure and 
purified by flash chromatography (hexanes/EtOAc = 8:1) to afford a semi-
solid (yield: 94 %). m.p: 168-170 
o
C; 
1H NMR (500 MHz, CDCl3) δ 8.41 (d, J 
= 8.8 Hz, 2H), 7.93 (d, J = 8.8 Hz, 2H), 4.02 (m, 1H), 3.88 (d, J = 11.2 Hz, 
1H), 3.78 (m, 2H), 3.50 (m, 2H), 3.38 (dd, J = 6.1, 11.4 Hz, 1H), 3.22 (m, 1H), 
3.05 (m, 1H), 2.30 (d, J = 14.6 Hz, 1H), 2.17 (m, 2H), 1.51 (m, 3H), 1.46 (s, 
9H) ppm; 
13
C NMR (125 MHz, CDCl3) δ 154.73, 150.43, 141.74, 128.75, 
124.59, 79.75, 71.42, 68.17, 53.37, 48.22, 44.06, 39.08, 38.62, 35.37, 28.91, 
28.42 ppm; IR (KBr): 2976, 1692, 1533, 1406, 1352, 1170 cm
-1
; HRMS (EI) 
calcd for C16H19ClN3O6S [M-t-BuO]
+





6-(chloromethyl)-2,2-diethyl-4-nosylmorpholine (2-4h): Synthesized 
according to the general procedure and purified by flash chromatography 




H NMR (500 MHz, CDCl3) δ 8.41 (d, J = 8.9 Hz, 2H), 7.94 (d, J = 8.9 Hz, 
2H), 4.00 (m, 1H), 3.86 (d, J = 11.1 Hz, 1H), 3.49 (m, 2H), 3.35 (dd, J = 6.6, 
11.4 Hz, 1H), 2.14 (d, J = 11.4 Hz, 1H), 2.10 (t, J = 10.8 Hz, 1H), 1.99 (m, 
1H), 1.60 (m, 1H), 1.48 (m, 1H), 1.44 (m, 1H), 0.85 (m, 6H) ppm; 
13
C NMR 
(125 MHz, CDCl3) δ 150.39, 145.59, 128.74, 124.51, 76.31, 67.94, 51.39, 
48.08, 44.34, 29.00, 22.24, 7.22, 6.79 ppm; IR (KBr): 2974, 1526, 1351, 1177, 
1099 cm
-1
; HRMS (EI) calcd for C15H21ClN2O5S [M]
+




6-(chloromethyl)-4-nosyl-2,2-dipropylmorpholine (2-4i): Synthesized 
according to the general procedure and purified by flash chromatography 




H NMR (500 MHz, CDCl3) δ 8.41 (d, J = 8.9 Hz, 2H), 7.93 (d, J = 8.9 Hz, 
2H), 4.00 (m, 1H), 3.86 (d, J = 11.0 Hz, 1H), 3.47 (m, 2H), 3.33 (dd, J = 6.6, 
11.4 Hz, 1H), 2.13 (d, J = 11.4 Hz, 1H), 2.08 (t, J = 10.9 Hz, 1H), 1.90 (m, 
1H), 1.57~1.20 (m, 7H), 0.96 (t, J = 7.3 Hz, 3H), 0.88 (t, J = 7.2 Hz, 3H) ppm; 
13
C NMR (125 MHz, CDCl3) δ 150.40, 141.99, 128.75, 124.50, 76.05, 67.91, 
51.99, 48.13, 44.35, 39.46, 32.59, 16.20, 15.97, 14.49, 14.47 ppm; IR (KBr): 
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2951, 1529, 1347, 1174, 1101 cm
-1
; HRMS (EI) calcd for C17H25ClN2O5S 
[M]
+
: 404.1173, found: 404.1184. 
 
 
2,2-dibenzyl-6-(chloromethyl)-4-nosylmorpholine (2-4j): Synthesized 
according to the general procedure and purified by flash chromatography 
(hexanes/EtOAc = 10:1) to afford a clear oil (yield: 86 %). 
1
H NMR (500 
MHz, CDCl3) δ 8.33 (d, J = 8.8 Hz, 2H), 7.84 (d, J = 8.8 Hz, 2H), 7.33 (m, 
5H), 7.14 (m, 3H), 7.03 (m, 2H), 4.39 (m, 1H), 3.82 (m, 1H), 3.57 (m, 2H), 
3.42 (dd, J = 6.4, 11.4 Hz, 1H), 3.24 (d, J = 14.0 Hz, 1H), 3.16 (d, J = 14.0 Hz, 
1H), 2.83 (d, J = 14.3 Hz, 1H), 2.58 (d, J = 14.3 Hz, 1H), 2.02 (d, J = 11.6 Hz, 
1H), 1.90 (t, J = 10.9 Hz, 1H) ppm; 
13
C NMR (125 MHz, CDCl3) δ 150.31, 
141.00, 136.24, 135.54, 130.78, 130.59, 128.82, 128.46, 127.81, 126.82, 
126.60, 124.36, 76.45, 68.25, 49.92, 47.93, 44.19, 43.10, 38.86 ppm; IR (neat): 
2923, 1531, 1350, 1173, 1087 cm
-1
; HRMS (EI) calcd for C18H18ClN2O5S [M-
PhCH2]
+
: 409.0625, found: 409.0627. 
 
 
6-(chloromethyl)-2,2-diisopropyl-4-nosylmorpholine (2-4k): Synthesized 
according to the general procedure and purified by flash chromatography 
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H NMR (500 MHz, CDCl3) δ 8.42 (d, J = 8.9 Hz, 2H), 7.95 (d, J = 8.9 Hz, 
2H), 4.05 (m, 1H), 3.81 (d, J = 11 Hz, 1H), 3.68 (dd, J = 1.6, 11.8 Hz, 1H), 
3.48 (dd, J = 4.6, 11.4 Hz, 1H), 3.37 (dd, J = 6.2, 11.4 Hz, 1H), 2.64 (m, 1H), 
2.23 (d, J = 11.8 Hz, 1H), 2.09 (t, J = 10.8 Hz, 1H), 1.99 (m, 1H), 1.06 (d, J = 
7.1 Hz, 3H), 0.99 (d, J = 7.1 Hz, 3H), 0.89 (d, J = 7.0 Hz, 3H), 0.87 (d, J = 7.0 
Hz, 3H) ppm; 
13
C NMR (125 MHz, CDCl3) δ 150.39, 141.94, 128.75, 124.53, 
78.75, 67.40, 47.96, 46.48, 44.65, 31.67, 28.30, 18.52, 18.31, 18.17, 16.15 
ppm; IR (KBr): 2967, 1531, 1350, 1158, 1088 cm
-1
; HRMS (EI) calcd for 
C11H21ClNO [M-Ns]
+
: 218.1312, found: 218.1312. 
2.4.4 One-pot synthesis of 2-4f using enantiopure (R)-epichlorohydrin 
 
To a mixture of N-bromosuccinimide (53 mg, 0.3 mmol), nosylamide (40 mg, 
0.2 mmol), and 2-1f (0.3 mmol) was stirred in (R)-epichlorohydrin (0.4 mL, 
99% ee) at -30 
o
C. The reaction was shielded from light and stirred at this 
temperature for 16 h. The solvent was then removed under reduced pressure 
and the residue was dissolved in MeCN (2 mL). K2CO3 (28 mg, 0.2 mmol) 
was added and the reaction mixture was stirred at 25 
o
C for 8 h. The solvent 
was then removed under reduced pressure and the residue was purified by 
flash column chromatography to yield 2-4f. 79% yield. []D
25
 -7.7 (c 1.0, 
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CHCl3, 99% ee). HPLC (Daicel Chiralpak IA, i-PrOH/hexane = 25/75, 0.6 
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Chapter 3  
Synthesis of Carnitine Acetyltransferase 
Inhibitor and Reboxetine via NBS-Induced 





The importance in ensuring the economic competitiveness of pharmaceutical 
industry while reducing the impact on environment has emerged in recent 
years.
1
 Multicomponent reaction (MCR), which three or more reactants are 
combined in a single chemical operation, is one of the ideal solutions for 
sustainable manufacture.
2
  Recently, we have developed a number of 
electrophilic MCR using N-bromosuccinimide as the initiator.
3
 Herein we are 
pleased to report the application of electrophilic MCR in the synthesis of 
bioactive 2-substituted morpholines 3.1 (a highly potent carnitine 
acetyltransferase inhibitor)
4
 and Reboxetine (3.2) (a norepinephrine  reuptake  
inhibitor,  marketed  as  an antidepressant by Pfizer)
5
. (Scheme 3.1) 
 
Scheme 3.1 NBS-Induced MCR in the Synthesis of 2-Substituted 
Morpholines 
 
Morpholines with substitutions at the -oxygen positions (2-substituted or 2,6-
disubstituted) are a class of molecules that possess interesting biological 
activities.
6
 Comparing to other substituted morpholines (e.g. 3-subsituted 





 enantioselective syntheses of 2-substituted morpholine systems are 
less reported.
8
 In one of our focuses on electrophilic MCRs using epoxide as 
the nucleophilic partner, epichlorohydrin was found to be effective which gave 
rise to the corresponding morpholine with a chloride handle (Scheme 3.1).
3d
 
We reasoned that this kind of functionalized morpholine scaffold will be very 
useful as an advanced intermediate of pharmaceutically important morpholines. 
 
3.2 Result and Discussion 
 
3.2.1 Synthesis of Carnitine Acetyltransferase Inhibitor 
Initially, acetonide protected diol, which could be synthesized in moderate 
yield according to reported procedure
9
, was used as the starting material. 
Unfortunately, the desired product was obtained in a very low yield, which 
made this choice unpractical. (Scheme 3.2) A conversion to bulky TBS 
protecting groups solved this problem very well.  
 
Scheme 3.2 Choosing Starting Material 
 
Thus, by mixing enantiopure (S)-epichlorohydrin, olefin 3.5, NBS, and NsNH2 
at -30 
o
C for 16 h, 3.6 was obtained in 72% yield (6:1 regioselectivity) 
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(Scheme 3.3). The unreacted (S)-epichlorohydrin was recovered by a simple 
distillation.  Attempted to scale up the reaction (using 2 grams of olefin 3.5) 
returned with only a slight decrease in reaction yield of 65%. Subsequent 
treatment of 3.6 with base under reflux furnished the multifunctionalized 
morpholine 3.7 in 83% yield.  
 
Scheme 3.3 Synthesis towards 3.12 
 
Attempts to install the cyanide group at this stage proved unpractical. 
The N-nosyl group in 3.7 was then removed to give the corresponding free 
amine which was then methylated to give N-methyl morpholine (3.8). Its 
treatment with sodium cyanide in DMSO at 100 
o
C accomplished 3.9. The 
cyanide moiety is a precursor for the introduction of carboxylate at the later 
stage. Global desilylation of 3.9 gave diol 3.10 in excellent yield. Direct 
transformation of 3.9 to lactone 3.11 via Pinner reaction was not successful. 
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When heating 3.9 in 6 N HCl for 12 h returned carboxylic acid 3.12 in 85% 
yield. Further trials to dehydrate 3.12 to give lactone 3.11 using various 
reagents were also fruitless. We suspected that the rigidity of the seven-
membered ring lactone might disfavor the cyclization process.
10
 (Scheme 3.3) 
 
After extensive experimentations, it was found that treatment of 3.10 with 1.0 
equivalent of n-BuLi followed by 1 equivalent of p-TsCl gave tosylate 3.13 (R 
= p-Ts) in 81% yield with the desired isomer 3.13a as the major product 
(3.13a:3.13b = 9:1, R=p-Ts). Interestingly, when MsCl was used in the same 
reaction, isomer 3.13b (R = Ms) was obtained as the major product 
(3.13a:3.13b = 1:4, R=Ms).  
 
Scheme 3.4 Selective Tosylation of 3.10 
 
We speculate that the n-butyl lithium might firstly coordinate to the nitrogen 
in 3.10 to give complex A. Due to the close proximity of the n-BuLi and the 
axial methylene OH, the deprotonation might proceed to give lithium alkoxide 
B (Scheme 3.4).
4a, 11
 The relatively smaller size MsCl might be able to react 
with the axial alkoxide in B to yield 3.13b (R=Ms). On the other hand, the 
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reaction between B and the bulkier p-TsCl might be disfavor. Instead, B could 
isomerize to C, which contains an equatorial OLi, and then react with p-TsCl 
to yield 3.13a (R=p-Ts). At this point, the two hydroxyl groups were 
differentiated which is important for the subsequent functionalization. 
 
After silylation of the hydroxyl group in 3.13a, the OTs group in 3.14 was 
removed by heating it with sodium boronhydride in DMSO at 100 
o
C (Scheme 
3.5). Some common alternative sulfonate reduction methods were also tried. 
The replacement of p-toluenesulfonate with iodide followed by hydrogenation 
gave a mixture of compound 3.15 and its isomer 3.16 (3.15:3.16 = 1:3). 
(Scheme 3.5) Although the mechanism needs further research, it is certain that 
the rearrangement occurs at the iodination step. 
 
Scheme 3.5 Detosylation to 3.15 
 
Treating 3.15 with MeI gave quaternary ammonium salt 3.17 in 91% yield. 
Finally, subjecting 3.17 in 6 N HCl at reflux transformed the cyanide into a 
carboxylic acid. The silyl protection was also removed under the same 
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conditions. Workup of the reaction mixture with aqueous base accomplished 
the desired carnitine acetyltransferase inhibitor 3.1. 
 
Scheme 3.6 Synthesis of 3.1 
 
3.2.2 Synthesis of Reboxetine 
Other than the synthesis of 3.1, this type of electrophilic MCR can also be 
applied to the formal synthesis of Reboxetine (3.2), a highly potent selective 
norepinephrine reuptake inhibitor. Racemic Reboxetine is marketed currently. 
However, recently it was found that the pure enantiomer (+)-(S,S)-Reboxetine 
(3.2) is significantly more active and a number of biologically studies are 
underway.
12
 As a result, an efficient and enantioselective entry towards the 




In this synthesis, we simply needed to use ethylene as the olefinic partner 
under the same optimized conditions, morpholine 3.18 with a methylene 
chloride handle at the 2-position could be achieved in 66% yield (Scheme 3.7). 
The structure of 3.18 was confirmed by an X-ray crystallographic study 
(Figure 3.1). Substitution of the chloride in 3.18 with potassium acetate 
followed by hydrolysis allowed for the introduction of an oxygen functionality, 
providing morpholine 3.19 in 81% yield. Subsequently, conventional 
protecting group manipulation accomplished hydroxyl morpholine 3.20 which 
is an important intermediate in the synthesis of Reboxetine (3.2). By using 
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appropriate hands of epichlorohydrin, one can synthesis both enantiomers of 
Reboxetine (3.2) efficiently. 
 
Scheme 3.7 Formal Synthesis of Reboxetine 
 
 
Figure 3.1 X-Ray Structure of 3.18 
 
3.3 Summary and Conclusion 
 
In summary, we have successfully applied the NBS-induced electrophilic 
MCR in the synthesis of biologically active 2,6,6-trisubsituted morpholine 3.1 
which is a potent carnitine acetyltransferase inhibitor. In addition, formal 
synthesis Reboxetine (3.2) was accomplished by using ethylene as the olefinic 
partner. This approach not only provides an efficient approach towards 
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biologically relevant 2-subsituted morpholine systems, but also offers 
flexibility in making drug analogues for further biological studies. 
 
3.4 Experimental Section 
 
3.4.1 Materials and general methods 
All reactions that required anhydrous conditions were carried by standard 
procedures under nitrogen atmosphere. Commercially available reagents and 
solvents were used without further treatment. Tetrahydrofuran (THF) was 
freshly distilled prior to use from sodium/benzophenone ketyl under N2. 
CH2Cl2 was freshly distilled from CaH2. Thin-layer chromatography (TLC) 
was performed with Merck silica gel 60 F254 precoated plates, and 
compounds were visualized with a spray of 5% (w/v) 
dodecamolybdophosphoric acid in ethanol and subsequent heating. Merck 60 




C NMR spectra were recorded on a Brüker DPX 300 (300 MHz and 75 MHz, 
respectively) or AMX 500 (500 MHz and 125 MHz, respectively). Data for 
1
H 
NMR spectra are reported as follows: chemical shift ppm (multiplicity, 
coupling constant (Hz), integration). Data for 
1
H NMR spectra are referenced 
to the centerline of CDCl3 7.26) as the internal standard. Data for 
13
C NMR 
spectra are referenced to the centerline of CDCl3 ( 77.0). High resolution 
mass spectra were obtained on a Finnigan/MAT 95XL-T spectrometer in ESI 




3.4.2 Synthesis of Carnitine Acetyltransferase inhibitor 3.1. 
 
3-tert-Butyldimethylsilyoxy-2-(tert-butyldimethylsilyoxy)methylpropene 
(3.5). To a stirred solution of dihydroxyacetone dimmer (2.0 g, 11.1 mmol) 
and imidazole (4.1 g, 60.0 mmol) in DMF (16 mL) was added tert-
butyldimthylsilyl chloride (9.0 g, 60.0 mmol) portion-wise at 0 
o
C. After 
stirring at room temperature for 6 h, water was added. The mixture was then 
extracted with EtOAc, washed with brine, dried with Na2SO4. After filtration 
through a short silica plug, the compound was determined to be pure enough 
for the subsequent Wittig reaction without additional purification. 
1
H NMR 
(500 MHz, CDCl3) δ 4.41 (s, 4H), 0.92 (s, 18H), 0.09 (s, 12H) ppm; 
13
C NMR 
(125 MHz, CDCl3) δ 208.53, 67.90, 25.76, 18.33, -5.55 ppm.  
 
To a stirred solution of methyltriphenylphosphonium bromide (10.0 g, 28.1 
mmol) in Et2O (300 mL), 2.0 M NaHMDS solution in THF (26.2 mmol, 13.1 
mL) was added drop-wise at 0 
o
C. After stirring at this temperature for 30 min, 
the ketone obtained from previous step was then added drop-wise. The 
mixture was further stirred for 4h at room temperature, after which water was 
added to quench the reaction. The mixture was extracted with EtOAc, washed 
with brine, dried with Na2SO4 and concentrated. The crude product was 
purified by filtration through a short silica plug (Hexane:EtOAc = 50:1) to 
give the product (6.4 g, 91% for two steps) as colorless oil: 
1
H NMR (500 
MHz, CDCl3) δ 5.08 (t, J = 1.3 Hz, 2H), 4.16 (t, J = 1.3 Hz, 4H), 0.91 (s, 18H), 
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0.07 (s, 12H) ppm; 
13
C NMR (125 MHz, CDCl3) δ 148.00, 109.04, 63.92, 




2-yloxy]-3-chloropropan-1-amine (3.6). Into the mixture of nosylamide (505 
mg, 2.5 mmol), NBS (534 mg, 3 mmol) and (S)-epichlorohydrin (5 mL) was 
added olefin (3.5) (948 mg, 3 mmol) at -30 
o
C. After stirring at this 
temperature for 16 h, the reaction was quenched by saturated sodium sulfite 
solution. The mixture was then extracted with EtOAc, washed with brine, 
dried with Na2SO4 and concentrated. The crude product was purified by flash 
chromatography (Hexane:EtOAc = 10:1) to give the product (1.2 g, 65%) as 




 -7.7 (c 1.0, CHCl3, 99% ee); 
1
H NMR (500 
MHz, CDCl3) δ 8.36 (d, J = 8.8 Hz, 2H), 8.06 (d, J = 8.8 Hz, 2H), 5.42 (t, J = 
6.0 Hz, 1H), 4.20 (m, 1H), 3.73-3.32 (m, 9H), 3.21(m, 1H), 0.89 (s, 9H) 
0.88(s, 9H), 0.09(s, 3H), 0.08(s, 3H), 0.07(s, 3H), 0.06(s, 3H) ppm; 
13
C NMR 
(125 MHz, CDCl3) δ 150.08, 145.80, 128.35, 124.36, 80.26, 71.62, 63.44, 
63.14, 45.04, 43.30, 34.40, 25.83, 25.76, 18.17, 18.09, -5.59, -5.62 ppm; IR 
(KBr): 3287, 2956, 2858, 1528, 1346, 1169, 1091, 838 cm
-1
; HRMS (ESI) 
calcd for C25H46BrClN2NaO7SSi2 [M+Na]
+
: 711.1328, found: 711.1346. 
Racemic-3.6 was separated by Daicel Chiralpak IA, i-PrOH/hexane = 5/95, 










nosylmorpholine (3.7). The CH3CN (15 mL) solution of compound 3.6 (1.0 g, 
1.5 mmol) and K2CO3 (414 mg, 3.0 mmol) was heated under reflux for 6 h. 
After cooling to room temperature, the mixture was extracted with EtOAc, 
washed with water and brine, dried with Na2SO4 and concentrated. The crude 
product was purified by flash chromatography (Hexane:EtOAc = 20:1) to give 




 +6.7 (c 
1.0, CHCl3); 
1
H NMR (500 MHz, CDCl3) δ 8.40 (d, J = 8.8 Hz, 2H), 7.94 (d, J 
= 8.8 Hz, 2H), 4.04 (m, 1H), 3.86 (d, J = 11.1 Hz, 1H), 3.80 (dd, J = 10.5, 15.2 
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Hz, 2H), 3.67(m, 2H), 3.49 (dd, J = 4.4, 11.4 Hz, 1H), 3.33 (m, 2H), 2.25 (d, J 
= 11.7 Hz, 1H), 2.12(t, J = 10.8 Hz, 1H), 0.91 (s, 9H), 0.84 (s, 9H), 0.09 (s, 
3H), 0.08 (s, 3H), 0.01 (s, 3H), -0.01 (s, 3H) ppm; 
13
C NMR (125 MHz, 
CDCl3) δ 150.47, 141.47, 128.93, 124.41, 76.69, 68.83, 64.91, 58.48, 48.14, 
46.97, 43.99, 25.79, 25.77, 18.20, 18.18, -5.41, -5.45, -5.49, -5.54 ppm; IR 
(KBr): 2957, 2858, 1528, 1356, 1172, 1102, 835 cm
-1
. HRMS (EI) calcd for 
C21H36ClN2O7SSi2 [M-t-Bu]
+
: 551.1470, found: 551.1466. 
 
2,2-Bis((tert-butyldimethylsilyloxy)methyl)-6-chloromethylmorpholine. 
The mixture of compound 3.7 (1.0 g, 1.6 mmol), lithium hydroxide 
monohydrate (344 mg, 8.2 mmol) and 1-propanethiol (742 L, 8.2 mmol) 
were stirred at room temperature in CH3CN (15 mL) for 6h. The mixture was 
then extracted with EtOAc, washed with water and brine, dried with Na2SO4 
and concentrated. The crude product was purified by flash chromatography 
(Hexane:EtOAc = 5:1) to give the product (590 mg, 85%) as clear oil: []D
26
 
+3.1 (c 1.0, CHCl3); 
1
H NMR (500 MHz, CDCl3) δ 3.97 (m, 1H), 3.93 (d, J = 
10.4 Hz, 1H), 3.79 (d, J = 10.4 Hz, 1H), 3.55 (d, J = 9.8 Hz, 1H), 3.43 (dd, J = 
5.1, 11.1 Hz, 1H), 3.33(m, 2H), 3.07 (dd, J = 2.1, 12.2 Hz, 1H), 2.98 (d, J = 
13.0 Hz, 1H), 2.60 (d, J = 13.0 Hz, 1H), 2.47(t, J = 11.5 Hz, 1H), 0.90 (s, 9H), 
0.87 (s, 9H), 0.07 (s, 6H), 0.03 (s, 6H) ppm; 
13
C NMR (125 MHz, CDCl3) δ 
75.36, 70.42, 66.08, 61.62, 48.87, 48.13, 45.33, 25.87, 25.82, 18.21, 18.18, -
5.43, -5.46, -5.50, -5.52 ppm; IR (neat): 3319, 2956, 2858, 1472, 1257, 1216, 
1105, 759 cm
-1
; HRMS (ESI) calcd for C19H43ClNO3Si2 [M+H]
+
: 424.2465, 





methylmorpholine (3.8). Into the 1,2-dichloroethane (20 mL) solution of 
compound from previous step (850 mg, 2.0 mmol), was added 37% 
formaldehyde (0.17 mL, 2.2 mmol) and NaBH(OAc)3 (466 mg, 2.2 mmol). 
After stirring at room temperature for 16h, the mixture was extracted with 
CH2Cl2, washed with water and brine, dried with Na2SO4 and concentrated. 
The crude product was purified by flash chromatography (Hexane:EtOAc = 
6:1) to give the product (762 mg, 87%) as clear oil: []D
26
 +7.0 (c 1.0, CHCl3); 
1
H NMR (500 MHz, CDCl3) δ 3.96 (m, 1H), 3.92 (d, J = 10.4 Hz, 1H), 3.72 
(m, 2H), 3.49 (dd, J = 4.9, 11.0 Hz, 1H), 3.34 (m, 2H), 2.88 (d, J = 10.8 Hz, 
1H), 2.70 (d, J = 11.6 Hz, 1H), 2.22 (s, 3H), 1.79 (d, J = 11.6 Hz, 1H), 1.71 (t, 
J = 10.8 Hz, 1H), 0.89 (s, 9H), 0.88 (s, 9H), 0.06 (s, 3H), 0.05 (s, 3H), 0.04 (s, 
6H) ppm; 
13
C NMR (125 MHz, CDCl3) δ 76.89, 69.73, 65.36, 59.17, 58.23, 
57.31, 46.60, 45.11, 25.88, 18.27, 18.24, -5.39, -5.42 ppm; IR (neat): 3020, 
2956, 2857, 1216, 758 cm
-1
; HRMS (ESI) calcd for C20H45ClNO3Si2 [M+H]
+
: 




methylmorpholine (3.9). The mixture of compound 3.8 (1.0 g, 2.3 mmol) and 
NaCN (336 mg, 6.9 mmol) was stirred in DMSO (10 mL) at 110 
o
C for 24 h. 
The mixture was then extracted with EtOAc, washed with water and brine, 
dried with Na2SO4 and concentrated. The crude product was purified by flash 
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chromatography (Hexane:EtOAc = 5:1) to give the starting material 
compound 11 (635 mg, 64%) and the product (296 mg, 30%, brsm 83%) as 
clear oil. []D
26
 -1.9 (c 1.0, CHCl3); 
1
H NMR (500 MHz, CDCl3) δ 4.01 (m, 
1H), 3.90 (d, J = 10.3 Hz, 1H), 3.72 (d, J = 10.3 Hz, 1H), 3.68 (d, J = 9.7 Hz, 
1H), 3.34 (d, J = 9.7 Hz, 1H), 2.79 (d, J = 10.8 Hz, 1H), 2.70 (d, J = 11.7 Hz, 
1H), 2.46 (m, 2H), 2.22 (s, 3H), 1.79 (m, 2H), 0.89 (s, 9H), 0.88 (s, 9H), 0.06 
(s, 3H), 0.05 (s, 3H), 0.04 (s, 6H) ppm; 
13
C NMR (125 MHz, CDCl3) δ 116.76, 
65.55, 65.18, 59.23, 58.98, 56.76, 46.38, 25.86, 25.84, 22.54, 18.25, 18.21, -
5.42, -5.45 ppm; IR (neat): 2953, 2857, 2247, 1468, 1255, 1104, 838, 777 cm
-1
; 
HRMS (ESI) calcd for C21H45N2O3Si2 [M+H]
+
: 429.2961, found: 429.2963.  
 
2,2-Bis(hydroxymethyl)-6-cyanomethyl-4-methylmorpholine (3.10). 
Compound 3.9 (900 mg, 2.1 mmol) was added into 1N HCl aqueous solution 
(10 mL) and stirred at r.t. for 10 h. After the reaction was completed, the 
solution was neutralized by sat. NaHCO3 solution. Water was then evaporated 
under reduced pressure. The crude product was purified by flash 
chromatography (CH2Cl2:CH3OH = 10:1) to give the product (395 mg, 94%) 




 -12.2 (c 1.0, CHCl3); 
1
H NMR (500 MHz, 
CDCl3) δ 4.41 (m, 1H), 3.94 (d, J = 11.7 Hz, 1H), 3.84 (d, J = 11.7 Hz, 1H), 
3.52 (d, J = 11.6 Hz, 1H), 3.45 (d, J = 11.6 Hz, 1H), 2.83 (m, 1H), 2.80 (d, J = 
11.7 Hz, 1H), 2.59 (dd, J = 5.8, 16.8 Hz, 1H), 2.50 (dd, J = 5.3, 16.8 Hz, 1H), 
2.29 (s, 3H), 2.21 (d, J = 11.7 Hz, 1H), 1.96 (t, J = 10.9 Hz, 1H) ppm; 
13
C 
NMR (125 MHz, CDCl3) δ 116.45, 75.97, 66.67, 66.26, 66.04, 58.39, 56.59, 
46.00, 22.80 ppm; IR (KBr): 2951, 2857, 2252, 1469, 1249, 1102, 844 cm
-1
; 
HRMS (ESI) calcd for C9H16N2NaO3 [M+Na]
+






(3.13a). Into the THF (10 mL) solution of compound 3.10 (400 mg, 2.0 mmol), 
was added 1.6 M n-BuLi solution in Hexane (1.3 mL, 2 mmol) at -78 
o
C. After 
stirring at this temperature for 30 min, THF (2 mL) solution of TsCl (382 mg, 
2 mmol) was added dropwise. The reaction was further stirred at -78 
o
C for 16 
h. The temperature was then raised to 0 
o
C, water was added to quench the 
reaction. The mixture was then extracted with EtOAc, washed with water and 
brine, dried with Na2SO4 and concentrated. The crude product was purified by 
flash chromatography (CH2Cl2:CH3OH = 10:1) to give the product (517 mg, 




 -2.8 (c 1.0, CHCl3); 
1
H NMR (500 
MHz, CDCl3) δ 7.78 (d, J = 8.2 Hz, 2H), 7.36 (d, J = 8.2 Hz, 2H), 4.25 (m, 
1H), 3.99 (d, J = 12.0 Hz, 1H), 3.91 (d, J = 10.0 Hz, 1H), 3.82 (d, J = 10.0 Hz, 
1H), 3.71 (d, J = 12.0 Hz, 1H), 2.81 (m, 2H), 2.45 (m, 5H), 2.25 (s, 3H), 2.01 
(d, J = 11.7 Hz, 1H), 1.88 (t, J = 10.9 Hz, 1H) ppm; 
13
C NMR (125 MHz, 
CDCl3) δ 145.19, 132.34, 129.96, 127.99, 116.28, 74.92, 71.00, 66.62, 62.97, 
58.33, 56.69, 45.95, 22.47, 21.63 ppm; IR (KBr): 2947, 2828, 2247, 1598, 
1465, 1355, 1172, 1073, 849 cm
-1
; HRMS (ESI) calcd for C16H22N2NaO5S 
[M+Na]
+
: 377.1142, found: 377.1150.  
 
2-tert-Butyldimethylsilyloxymethyl-2-tosyloxymethyl-6-cyanomethyl-4-
methylmorpholine (3.14). To a stirred solution of compound 3.13a (350 mg, 
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1 mmol) and imidazole (204 mg, 3 mmol) in DMF (2 mL) was added tert-
butyldimthylsilyl chloride (225 mg, 1.5 mmol) at 0 
o
C. After stirring at room 
temperature for 8 h, water was added. The mixture was then extracted with 
EtOAc, washed with brine, dried with Na2SO4. The crude product was purified 
by flash chromatography (Hexane:EtOAc = 5:1) to give the product (430 mg, 
92 %) as clear oil. []D
23
 +3.2 (c 1.0, CHCl3); 
1
H NMR (500 MHz, CDCl3) δ 
7.78 (d, J = 8.3 Hz, 2H), 7.33 (d, J = 8.2 Hz, 2H), 3.99 (d, J = 9.7 Hz, 1H), 
3.94 (m, 1H), 3.87 (d, J = 9.7 Hz, 1H), 3.80 (d, J = 10.2 Hz, 1H), 3.73 (d, J = 
10.2 Hz, 1H), 2.73 (d, J = 10.8 Hz, 1H), 2.69 (d, J = 11.6 Hz, 1H), 2.43 (s, 
3H), 2.37 (m, 2H), 2.21 (s, 3H), 1.84 (d, J = 11.6 Hz, 1H), 1.78 (t, J = 10.8 Hz, 
1H), 0.82 (s, 9H), 0.01 (s, 3H), 0.00 (s, 3H) ppm; 
13
C NMR (125 MHz, CDCl3) 
δ 144.75, 132.71, 129.78, 127.99, 116.41, 75.71, 71.18, 66.08, 59.43, 58.54, 
54.96, 46.06, 25.67, 22.32, 21.57, 18.02, -5.58, -5.68 ppm; IR (neat): 2952, 
2856, 2250, 1363, 1178, 1098, 989, 839 cm
-1
; HRMS (ESI) calcd for 
C22H36N2NaO5SSi [M+Na]
+
: 491.2006, found: 491.2021.  
 
2-tert-Butyldimethylsilyloxymethyl-6-cyanomethyl-2,4-
dimethylmorpholine (3.15): The mixture of compound 3.14 (200 mg, 0.43 
mmol), NaBH4 (82 mg, 2.15 mmol) in DMF (5 mL) was heated at 100 
o
C for 
8h, water was then added. The mixture was then extracted with EtOAc, 
washed with brine, dried with Na2SO4. The crude product was purified by 
flash chromatography (Hexane:EtOAc = 6:1) to give the product (55 mg, 43 %) 
as oil. []D
25
 +11.4 (c 1.0, CHCl3); 
1
H NMR (500 MHz, CDCl3) δ 3.99 (m, 
1H), 3.89 (d, J = 9.3 Hz, 1H), 3.51 (d, J = 9.3 Hz, 1H), 2.77 (m, 2H), 2.48 (dd, 
J = 5.7, 16.7 Hz, 1H), 2.43 (dd, J = 6.3, 16.7 Hz, 1H), 2.22 (s, 3H), 1.77 (t, J = 
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10.8 Hz, 1H), 1.68 (d, J = 11.7 Hz, 1H), 1.13 (s, 3H), 0.89 (s, 9H), 0.05 (s, 6H) 
ppm; 
13
C NMR (126 MHz, CDCl3) δ 116.87, 75.27, 65.94, 63.59, 59.65, 59.02, 
46.10, 25.83, 23.59, 22.78, 18.19, -5.44, -5.47 ppm; IR (neat): 2932, 2856, 
2360, 1462, 1255, 1100, 853, 777 cm
-1
; HRMS (ESI) calcd for C15H31N2O2Si 
[M+1]
+




trimethylmorpholin-4-ium iodide (3.17): Compound 3.15 (40 mg, 0.13 
mmol) was dissolved in anhydrous Et2O (5 mL), MeI (185 mg, 1.3 mmol) was 
then added. The mixture was stirred at r.t. for 2d. The precipitate (54 mg, 





 + 13.6 (c 1.0, CH3OH); 
1
H NMR (500 MHz, CD3OD) δ 4.65 (m, 
1H), 4.13 (d, J = 11.0 Hz, 1H), 3.80 (dd, J = 1.8, 13.5 Hz, 1H), 3.64 (d, J = 
12.8 Hz, 1H), 3.60 (d, J = 10.9 Hz, 1H), 3.35 (s, 3H), 3.34 (s, 3H), 3.25 (m, 
1H), 3.18 (d, J = 13.5 Hz, 1H), 2.88 (dd, J = 4.6, 17.1 Hz, 1H), 2.78 (dd, J = 
6.5, 17.1 Hz, 1H), 1.34 (s, 3H), 0.96 (s, 9H), 0.16 (s, 6H) ppm; 
13
C NMR (125 
MHz, CD3OD) δ 117.07, 75.40, 65.67, 63.40, 63.36, 59.54, 51.47, 27.34, 
27.23, 26.32, 22.34, 19.03, -5.34, -5.47 ppm; IR (KBr): 2928, 2850, 2253, 
1470, 1257, 1098, 849, 777 cm
-1
; HRMS (ESI) calcd for C16H33N2O2Si [M-I]
+
: 






Compound 3.17 (50mg, 0.11 mmol) in 6N HCl (4 mL) was refluxed for 4h. 5% 
NaOH was added to neutralize the mixture. The product was purified 
following the same procedure reported. Compound 18 was obtained (18mg, 
72%). []D
23
 +21.2 (c 0.05, CHCl3); 
1H NMR (500 MHz, MeOD) δ 4.55 (m, 
1H), 3.85 (d, J = 11.9 Hz, 1H), 3.78 (dd, J = 1.8, 13.4 Hz, 1H), 3.68 (d, J = 
11.8 Hz, 1H), 3.58 (ddd, J = 1.8, 1.9, 12.6 Hz, 1H), 3.33 (s, 3H), 3.27 (s, 3H), 
3.13 (dd, J = 11.9, 13.6 Hz, 1H), 3.10 (d, J = 13.6 Hz, 1H), 2.45 (dd, J = 6.9, 
15.5 Hz, 1H), 2.33 (dd, J = 6.1, 15.5 Hz, 1H), 1.27 (s, 3H) ppm; 
13
C NMR 
(125 MHz, MeOD) δ 177.16, 74.73, 64.96, 64.89, 63.85, 59.38, 51.43, 42.07, 
26.75 ppm; HRMS (ESI) calcd for C10H20NO4 [M+1]
+
: 218.1387, found: 
218.1386. 
 




2-Chloromethyl-4-nosylmorpholine (3.18): Nosylamide (202 mg, 1.0 mmol) 
and NBS (214 mg, 1.2 mmol) were dissolved in epichlorohydrin (2 mL) at -30 
o
C. With the protection of N2, ethylene gas was then bubbled into the solution 
for 2 h. After stirring at this temperature for 24 h, the reaction was quenched 
by saturated sodium sulfite solution. The mixture was then extracted with 
EtOAc, washed with brine, dried with Na2SO4 and concentrated. The crude 
product was used in the next step without further purification. 
Into the crude product was added CH3CN (10 mL) and K2CO3 (276 mg, 2.0 
mmol), the mixture was then stirred at r.t. for 16 h. After the reaction was 
complete, the mixture was extracted with EtOAc, washed with water and brine, 
dried with Na2SO4 and concentrated. The crude product was purified by flash 
chromatography (Hexane : EtOAc = 5:1) to give compound 1 (211 mg, 66% 
for 2 steps) as solid:  m.p.: 132 – 135 oC; 1H NMR (500 MHz, CDCl3) δ 8.42 
(d, J = 8.8 Hz, 2H), 7.96 (d, J = 8.8 Hz, 2H), 4.05 – 3.93 (m, 1H), 3.87 – 3.77 
(m, 2H), 3.73 (td, J = 11.5, 2.7 Hz, 1H), 3.67 – 3.58 (m, 1H), 3.55 (dd, J = 
11.7, 4.7 Hz, 1H), 3.46 (dd, J = 11.7, 5.9 Hz, 1H), 2.53 (td, J = 11.5, 3.4 Hz, 
1H), 2.34 (t, J = 11.1 Hz, 1H); 
13
C NMR (125 MHz, CDCl3) δ 150.46, 141.44, 
128.93, 124.53, 74.35, 65.99, 47.98, 45.22, 43.59; IR (KBr): 3108, 2992, 1528, 
1352, 1177, 1107 cm
-1




2-Acetoxymethyl-4-nosylmorpholine : Into the DMF (5 mL) solution of 
compound 3.18 (160 mg, 0.5 mmol) was added potassium acetate (490 mg, 5 
mmol). Under the protection of N2, the reaction mixture was stirred at 90 
o
C 
for 16 h. The mixture was then extracted with EtOAc, washed with water and 
brine, dried with with Na2SO4 and concentrated. The crude product was 
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purified by flash chromatography (Hexane : EtOAc = 3:1) to give the product  
(139 mg, 81%) as light-yellow solid: m.p.: 95 – 97 oC; 1H NMR (500 MHz, 
CDCl3) δ 8.42 (d, J = 8.7 Hz, 2H), 7.95 (d, J = 8.8 Hz, 2H), 4.06 (qd, J = 11.8, 
5.2 Hz, 2H), 3.98 (dd, J = 11.8, 1.9 Hz, 1H), 3.82 – 3.77 (m, 1H), 3.75 – 3.66 
(m, 2H), 3.61 (d, J = 11.4 Hz, 1H), 2.51 (td, J = 11.5, 3.4 Hz, 1H), 2.26 (t, J = 
10.9 Hz, 1H), 2.08 (s, 3H); 
13
C NMR (125 MHz, CDCl3) δ 170.49, 150.44, 
141.36, 128.94, 124.50, 73.05, 65.88, 63.95, 47.30, 45.28, 20.74; IR (KBr): 
3111, 2980, 1749, 1542, 1351, 1248, 1167 cm
-1
; HRMS (EI) calcd for 
C13H16N2O7S [M]
+
:344.0678, found: 344.0690. 
2-Hydroxymethyl-4-nosylmorpholine (3.19): Compound from previous step 
(172 mg, 0.5 mmol) was dissolved in 5 mL CH3OH/H2O (1:1), K2CO3 (207 
mg, 1.5 mmol) was then added. The reaction mixture was stirred at r.t. for 16 
h. After usual workup, the crude product was purified by flash 
chromatography (Hexane:EtOAc = 1:1) to give 3.19 (140 mg, 93%) as light-
yellow powder: m.p. 173 – 174 oC; 1H NMR (500 MHz, MeOD) δ 8.47 (d, J = 
8.9 Hz, 2H), 8.03 (d, J = 8.9 Hz, 2H), 3.94 (ddd, J = 11.5, 3.2, 1.3 Hz, 1H), 
3.72 – 3.67 (m, 1H), 3.64 (td, J = 11.5, 2.7 Hz, 1H), 3.61 – 3.46 (m, 4H), 2.47 
(td, J = 11.5, 3.4 Hz, 1H), 2.26 (dd, J = 11.5, 10.0 Hz, 1H); 
13
C NMR (125 
MHz, MeOD) δ 151.97, 142.60, 130.40, 125.55, 77.14, 66.98, 63.59, 46.88; 
IR (KBr): 3450, 3114, 2921, 1530, 1350, 1176 cm
-1
 HRMS (EI) calcd for 
C11H14N2O6S [M]
+
:302.0573, found: 302.0575. 
2-Hydroxymethyl-4-bocmorpholine (3.20): The mixture of compound 3.19 
(121 mg, 0.4 mmol), lithium hydroxide monohydrate (84 mg, 2.0 mmol) and 
1-propanethiol (18 L, 2.0 mmol) were stirred at room temperature in CH3CN 
87 
 
(4 mL) for 8 h. After the reaction was complete, the solvent was evaporated. 
The mixture was used in the next step without further purification.  
The mixture was stirred in 8 mL of CH2Cl2/H2O (1:1), NaOH (32 mg, 0.8 
mmol) and Boc2O (174 mg, 0.8 mmol) were added subsequently. The reaction 
completed in 4 h, after usual workup, the crude product was purified by flash 
chromatography (Hexane:EtOAc = 1:1) to afford 3.20 (70 mg, 80 %). 
1
H 
NMR (500 MHz, CDCl3) δ 3.88 – 3.86 (m, 3H), 3.69 – 3.44 (m, 4H), 2.90 (bs, 
1H), 2.72 (bs, 1H), 2.34 (t, J = 5.4 Hz, 1H), 1.44 (s, 9H); 
13
C NMR (125 MHz, 
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Chapter 4  
Bromonium Ion Induced Aminocyclization-






Although a fundamental organic reaction, electrophilic activation of 
olefins by halonium ion
1
 revives in recent years mainly in two areas: 1) 
catalytic and asymmetric induction of halonium ion;
2
 2) halonium ion 
induced cascade or multicomponent reactions and their synthetic 
applications.
3
 Bromonium ion induced cyclic ether ring expansion 
cascade reactions received much attention due to their facile construction 
of the scaffolds of corresponding natural products (Scheme 4.1, eq 1).
3
 
Recently, our group reported bromonium ion induced multicomponent 
reactions which involved a cyclic ether ring opening cascade. When 
epoxide was applied as the nucleophilic partner, this strategy has been 





As the chemical analogue of epoxide, aziridine displays similar 
reactivity.
5
 Due to the highly strained ring system, the lone pair of 
nitrogen can hardly resonate with neighboring conjugated group, which 
results in a certain degree of nucleophilicity of aziridine.
5
 We reasoned 
that an aziridine should be able to attack a bromonium ion, leading to an 
aziridinium ion intermediate which could then be attacked by other 
nucleophiles (Scheme 4.1, eq 3), although this was rarely reported. A 
single example of bromoaminocyclization using an aziridine was reported 
with elemental bromine as the halogen source, which resulted in the 
synthesis of a dibrominated meso-morpholine in 43% yield.
6
 In this 
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chapter, the discovery of a novel and highly stereoselective 
bromoaminocyclization of olefinic aziridine cascade reaction is presented. 
The reaction resulted in the formation of enantiopure substituted 
azepanes, and no piperidine was detected. Functionalized azepanes are 
useful in various areas such as biomedical chemistry.
7
 It is important to 
note that direct cyclization (e.g. halocyclization) of olefinic amine/amide 
to azepane is not trivial as such kind of reaction suffers from high entropy 
and enthalpy barrier.
8
 In addition, enantioselective approach towards 
substituted azepane synthesis remains under-exploited.
9
 This 
methodology can be considered as a detour for the direct seven-





Scheme 4.1 Bromonium Ion Induced Cascade Reaction 
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4.2 Result and Discussion 
 
To verify the hypothesis, enantiopure olefinic aziridine 4.1a, which could 
be readily synthesized from L-glutamic acid, was subjected to the 
investigation. N-Bromosuccinimide (NBS) and NsNH2 were used as the 
halogenating agent and the nucleophilic partner, respectively. 
Interestingly, upon the halogen source initiation, the cyclized product 
azepane 4.2a was obtained in 54% yield when using dichloromethane as 
the solvent.  A quick survey on some common organic solvents revealed 
that the reaction worked best in ethyl acetate and 4.2a was returned with 
82% yield (Table 4.1, entry 11). As a matter of fact, some other polar 
aprotic solvents, such as THF, CH3CN, Acetone, also gave satisfactory 
yield (Table 4.1, entry 8 – 10). 













1 CH2Cl2 25 0.5 54 
2 CH2Cl2 0 2 56 
3 CH2Cl2 -20 10 73 
4 Hexane 25 24 < 5 
5 Toluene 25 24 43 
6 CHCl3 25 12 49 
7 Et2O 25 24 59 
8 THF -20 10 75 
9 CH3CN -20 10 75 
10 Acetone -20 10 78 
11 EA -20 10 82 
Reactions were carried out with compound 4.1a (0.2 mmol), NBS (0.3 
mmol), and NsNH2 (0.3 mmol) in solvent (4 mL). 
a
 Isolated yield. 
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After subsequent optimization of the reaction temperature, it was found 
that the reaction worked better at –30 oC which returned with 88 % yield 
of the desired product (Table 4.2, entry 1–3). The yield was further 
improved to 90 % when freshly recrystallized NBS was applied (entry 4). 
The reaction concentration could be increased to 0.1 M (entry 5) with 
slightly improved yield, while lowering the concentration (0.025 M, entry 
6) had a significant detrimental effect. The optimized conditions were 
then applied to a large scale reaction (entry 7); azepane 4.2a was obtained 
in 88 % yield starting from 1.0 gram of 4.1a. Other halogen sources were 
also investigated.  N-Chlorosuccinimide  (NCS)  (entry  8)  and  N-
iodosuccinimide (NIS) (entry 9) were not as effective as NBS in 
mediating the reaction, while some other commonly used brominting 
agents such as N-bromophthalimide (NBP) (entry  10)  and  2,2-dimethyl-
1,3-dibromohydatoin  (DMDBH) (entry 11) gave comparable yields. 
Finally, the effect of the N-protecting group was examined. Cbz activated 
aziridine (entry 13) gave considerably higher yield than that of the Ts 
group (entry 12). It is noteworthy that the reaction is highly chemo-, 
enantio-, and stereoselective in which out of eight possible stereoisomers 
(with three stereogeneric centers), 4.2a was furnished exclusively and no 
piperidine product (anti-Markovnikov) was detected. The absolute 
configuration of 4.2a was established unambiguously by an X-ray 
crystallographic study of its analogue 4.2a-Bn (Figure 4.1), which could 
be easily obtained after deprotecting Nosyl group and installing the 
Benzyl protecting group. The seven-member ring skeleton was also 
confirmed by HMBC spectrum of compound 4.2b. 
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1 Boc NBS –20 10 82 
2 Boc NBS  –30 48 88 
3 Boc NBS  –40 72 86 
4
c
 Boc NBS  –30 48 90 
5
c,d
 Boc NBS  –30 48 91 
6
c,e 
Boc NBS  –30 48 79 
7
c,f
 Boc NBS  –30 48 88 
8
 
Boc NCS –30 48 <5 
9 Boc NIS –30 48 11 
10 Boc NBP –30 48 89 
11 Boc DMDBH –30 48 86 
12 Ts NBS –30 48 31 
13 Cbz NBS –30 48 82 
a
 Reactions were carried out with compound 4.1 (0.2 mmol), halogen 





 Recrystallized NBS was used. 
d
 2 mL of EtOAc (0.1 M) 
was used. 
e
 8 mL of EtOAc (0.025 M). 
f
 1.0g scale, 0.1 M. NBS = N-
Bromosuccinimide. NCS = N-Chlorosuccinimide. NIS = N-
Iodosuccinimide. NBP = N-Bromophthalimide. DMDBH = 2,2-Dimethyl-
1,3-dibromohydatoin. 
 
Figure 4.1 X-Ray Structure of 4.2a-Bn (X = Br, R = Boc) 
Having identified the optimal system, we then explored the scope of the 
reaction as listed in Table 4.3. In all cases, good yields of azepanes were 
obtained with each product isolated as a single diastereoisomer. No 
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bromination on the aromatic ring or at the benzylic position was observed 
even for the electron-rich substituted systems (4.2b–c, i–j). Compared 
with other substrates, ortho-CH3 substituted substrate 4.2b gave 70 % 
yield, presumably due to the steric repulsion between the bulky Boc 
group and the ortho substitution. The electronic effect appeared to be less 
dominating in this type of reaction. Halogen substituted substrates 4.1d–f 
and ester substrate 4.1g also performed well. Additionally, the 
heteroaromatic substrate 4.1k was well tolerated to give 73 % yield of the 
desired product. 





 Reactions were carried out with olefinic aziridine 4.1 (0.1 mmol), 
recrystallized NBS (0.15 mmol), and NsNH2 (0.15 mmol) in anhydrous 
EtOAc (1 mL). The yields were isolated yields. 
b
 The corresponding 




4.3 Synthetic Applications 
 
Substituted azepane is a pharmacophore of many interesting bioactive 
compounds.
7
 In addition, 4.2 is a versatile synthetic precursor of many 
functional molecules. For instance, the Boc group in azepane 4.2a could 
be removed under acidic environment to yield the corresponding 
deprotected amine, which was transformed into azabicyclo[3.1.0]hexane 
derivative 4.3 simultaneously (Scheme 4.2). Bicyclo[3.1.0] system 4.3 
was found to be unstable when it was concentrated. Nonetheless, this 
active intermediate could be stored in methylene chloride (0.03 M) at 0 
o
C for a month without apparent decomposition.
11
 Subsequent reaction 
with acetic acid gave rise to the piperidine derivative 4.4. The 
stereochemistry was determined by an X-ray crystallographic study on 
the tosylate derived 4.5.  
 
Scheme 4.2 Synthesis of Piperidine 
 
Other than acetic acid, 4.3 could react with p-fluorothiophenol and 
trimethylsilyl azide to furnish the thioether 4.6 and the azide derivative 
4.9, respectively (Scheme 4.3). For thioether 4.6, subsequent cyclization 
reaction by connecting the two nitrogen atoms gave rise to bicyclic 
systems 4.7 and 4.8; these skeletons consist of a rigid tertiary amine 
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moiety which resembles the cinchona alkaloid scaffold. The antipodes of 
4.7 and 4.8 can readily be prepared from ent-4.1 which can result in an 
enantiomeric pair of privileged catalyst skeletons’ mimic.12 In addition, 
4.8 contains a bridgehead amide which potentially possesses unusual 
physical and chemical properties.
13
 The chemical structure of compound 
4.8 was confirmed by 2D-NMR. 
 
On the other hand, azide 4.9 could be converted into 1,2-diamine 4.10 by 
Staudinger reduction. Treatment of 4.10 with triphosgene under basic 
condition furnished urea 4.11. These amine systems consist of modifiable 
handles which can potentially be utilized as metal ligands
14
 and 
organocatalysts’ building blocks.15 
 
Scheme 4.3 Synthesis of 4.6-4.11 
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4.4 Mechanism Study 
 
Towards a better understanding on the mechanism, the stability of 
aziridine was examined in the presence of the halogenating agent 
(Scheme 4.4). No reaction was observed when mixing aziridine 4.12 with 
NBS and NsNH2 in ethyl acetate at 25 
o
C for 24 h. This suggests that the 
aziridine ring was not pre-opened before the aminocyclization step. 
 
Based on this result and our previous experience on the electrophilic 
halogenation reactions, we believe that NBS might be activated by 
NsNH2. The cyclization of 4.1a in the absence of either NBS or NsNH2 
were also performed which returned with no reaction. This further 
supports the hypothesis. Electrophilic addition of activated NBS to the 
olefin in substrate 4.1 would give bromonium ion intermediate A. Acting 
as a nucleophile, the aziridine could then react with bromonium ion and 
gave aziridinium ion intermediate B. Finally, NsNH2 would open the ring 
to afford the desired azepane compound 4.2. The excellent 
stereospecificity in the formation of 4.2 also suggests that the 
nucleophilic attacks in A and B were in SN2 manner. 
 
Scheme 4.4 Proposed Mechanism of the Cyclization 
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Other than substrate 4.1, other skeletons were also investigated. 
Preliminary result shows that this methodology was also applicable to 
enantiopure olefinic aziridine 4.13 to give highly functionalized 
piperidine 4.14 (Scheme 4.5). This result holds promise for further 
expansion of this methodology. 
 
Scheme 4.5. Preliminary Study on the Cyclization of 4.13 
 
4.5 Summary and Conclusion 
 
In conclusion, a novel multicomponent, bromonium ion induced 
aminocyclization-aziridine ring expansion reaction was developed. The 
resulting enantiopure azepanes could be utilized in the preparation of 
functionalized piperidines and rigid amine systems. Further application to 
other substrates is underway. 
 
4.6 Experimental Section 
 
4.6.1 Materials and general methods 
Anhydrous reactions were carried out by standard procedures under 
nitrogen atmosphere. Unless otherwise indicated, all commercially 
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available reagents were used without further purification; all solvents 
were freshly distilled under nitrogen from appropriate drying agents prior 
to use. Thin-layer chromatography (TLC) was performed with Merck 
silica gel 60 F254 precoated plates. Merck 60 (0.040-0.063 mm) mesh 
silica gel was used for flash chromatography. Melting points were 





spectra were recorded on a Bruker AMX 500 (500 MHz and 125 MHz, 
respectively) using residue solvent peaks as internal standards. IR spectra 
were recorded on a BIO-RAD FTS 165 FT-IR spectrophotometer. High 
resolution mass spectra were obtained on a Finnigan/MAT 95XL-T 
spectrometer in ESI or EI mode. Optical rotations were measured on a 
Jasco DIP-1000 polarimeter using a 10 mm path-length cell at 589 nm. 
Analytical chiral HPLC was performed with a Shimadzu utilizing a 
Daicel Chiralpak IA column (4.6 mm x 25 cm). 
 
4.6.2 Substrate Synthesis 
 





(3.69 g, 10 mmol) in toluene (10 mL) was refluxed for 24 h. After the 
reaction mixture was cooled to r.t., the liquid was decanted. The semi-
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solid obtained was used directly in the next step without further 
purification. 
Into the anhydrous THF (20 mL) solution of compound b (10 mmol) was 
added PhLi (10 mmol, prepared by reported procedure
17
 which 
spontaneously contains equal amount of LiBr) at –78 oC. The cooling 
bath was removed and the reaction mixture was warmed to r.t. over 15 
min. After 30 min, the reaction mixture was re-cooled to –78 oC and 
benzaldehyde (1.06 g, 10 mmol) was added dropwise. After 5 min, when 
complete decolorization had occurred, the second equivalent of PhLi (11 
mmol) was added dropwise to form a cherry-red solution. This solution 
was stirred for 30 min at –78 oC, then allowed to reach r.t. over 15 min. 
After 30 min the resulting β-oxido ylide was re-cooled to –78 oC, t-BuOH 
(740 mg, 10 mmol) was then added dropwise, followed by KOt-Bu (10 
mmol in t-BuOH, 1M). After 30 min at –78 oC, the temperature was 
slowly raised to r.t. over 30 min and the reaction mixture was further 
stirred for 2 h. The reaction mixture was then poured into water (20 mL), 
extracted with Et2O (3x15 mL), dried (MgSO4) and evaporated under 
reduced pressure.
18
 Purification of the residue by column 
chromatography gave the product c as colorless oil (2.5 g, 75%). 
tert-Butyl (4S)-4-[(3E)-4-phenyl-3-buten-1-yl)]-2,2-
dimethyloxazolidine-3-carboxylate (c):  []D
25
 +30.9 (c 1.0, CHCl3); 
1
H 
NMR (500 MHz, DMSO) δ 7.37 – 7.15 (m, 5H), 6.44 (d, J = 15.9 Hz, 
1H), 6.26 (dt, J = 15.8, 6.7 Hz, 1H), 3.95 (dd, J = 8.8, 6.0 Hz, 1H), 3.89 – 
3.86 (m, 1H), 3.79 – 3.72 (m, 1H), 2.32 – 2.12 (m, 2H), 1.90 – 1.83 (m, 
1H), 1.74 – 1.64 (m, 1H), 1.52 (s, 3H), 1.45 (s, 12H); 13C NMR (125 
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MHz, DMSO) δ 150.84, 137.00, 129.58, 129.38, 127.73, 126.13, 125.20, 
92.34, 78.42, 66.14, 56.06, 32.20, 28.20, 27.58, 26.31, 23.39; IR (KBr): 
3016, 2981, 2936, 1687, 1393, 1173, 1089 cm
-1
; HRMS (ESI) calcd for 
C20H29NNaO3 [M+Na] 
+
 : 354.0240, found: 354.0245. 
Compound c (1.7 g, 5 mmol) was dissolved in 20 mL methanol, into the 
solution was added TsOH (287 mg, 1.5 mmol). After stirring at r.t. for 2 
h, the reaction was quenched by saturated NaHCO3 solution. The mixture 
was then extracted by EtOAc, washed with brine, dried and evaporated 
under reduced pressure. The residue was purified by column 
chromatography to provide product d (1.2 g, 82%). 
tert-Butyl N-[(1S)-1-hydroxymethyl-(3E)-4-phenyl-3-buten-1-




 –15.1 (c 1.0, CHCl3); 
1
H 
NMR (500 MHz, CDCl3) δ 7.35 – 7.15 (m, 5H), 6.40 (d, J = 15.8 Hz, 1H), 
6.20 (dt, J = 15.7, 6.9 Hz, 1H), 4.76 (bs, 1H), 3.68 (d, J = 8.7 Hz, 2H), 
3.59 – 3.55 (m, 1H), 2.36 – 2.20 (m, 2H), 1.75 – 1.65 (m, 1H), 1.65 – 
1.55 (m, 1H), 1.45 (s, 9H); 
13
C NMR (125 MHz, CDCl3) δ 156.41, 
137.52, 130.57, 129.54, 128.44, 126.96, 125.95, 79.64, 65.68, 52.42, 
31.18, 29.52, 28.35; IR (KBr): 3441, 3020, 1699, 1505, 1167 cm
-1
; 
HRMS (ESI) calcd for C17H25NNaO3 [M+Na] 
+
 : 314.1727, found: 
314.1734. 
To a solution of d (2.9 g, 10 mmol) and TsCl (2.3 g, 12 mmol) in 200 mL 
dry Et2O was added freshly powdered KOH (2.2 g, 40 mmol) at r.t. The 
stirred mixture was refluxed until TLC indicates disappearance of the 
reactants. The reaction was quenched by pouring in iced water.
19
 The 
organic phase was separated, washed with brine, dried with MgSO4 and 
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the solvent was removed under reduced pressure. The aziridine 4.1a was 
purified by flash chromatography (2.2 g, 80%). 
 
tert-Butyl (2S)-2-[(3E)-4-phenyl-3-buten-1-yl)]-1-aziridine carboxylic 
acid (4.1a): []D
25
 +42.7 (c 1.0, CHCl3); 
1
H NMR (500 MHz, CDCl3) δ 
7.35 – 7.18 (m, 5H), 6.44 (d, J = 15.8 Hz, 1H), 6.26 (dt, J = 15.8, 6.9 Hz, 
1H), 2.48 – 2.34 (m, 3H), 2.28 (d, J = 6.1 Hz, 1H), 1.95 (d, J = 3.8 Hz, 
1H), 1.64 (dd, J = 14.2, 7.0 Hz, 2H), 1.46 (s, 9H); 
13
C NMR (125 MHz, 
CDCl3) δ 162.58, 137.58, 130.60, 129.49, 128.48, 126.97, 125.96, 80.98, 
37.65, 32.17, 31.72, 30.43, 27.93; IR (KBr): 2980, 2931, 1712, 1312, 
1164 cm
-1
; HRMS (ESI) calcd for C17H23NNaO2 [M+Na] 
+





carboxylic acid (4.1b): []D
25
 +50.8 (c 1.0, CHCl3); 
1
H NMR (500 MHz, 
CDCl3) δ 7.44 – 7.06 (m, 4H), 6.63 (d, J = 15.7 Hz, 1H), 6.13 (dt, J = 
15.6, 6.9 Hz, 1H), 2.48 – 2.38 (m, 3H), 2.33 (s, 3H), 2.29 (d, J = 6.1 Hz, 
1H), 1.96 (d, J = 3.8 Hz, 1H), 1.66 (q, J = 6.8 Hz, 2H), 1.46 (s, 9H); 
13
C 
NMR (125 MHz, CDCl3) δ 162.58, 136.74, 134.96, 130.86, 130.15, 
128.46, 126.93, 126.00, 125.48, 80.99, 37.69, 32.29, 31.74, 30.71, 27.94, 
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19.80; IR (KBr): 2980, 2932, 1717, 1311, 1157, 966 cm
-1
; HRMS (ESI) 
calcd for C18H25NNaO2 [M+Na] 
+




carboxylic acid (4.1c): []D
25
 +48.9 (c 1.0, CHCl3); 
1
H NMR (500 MHz, 
CDCl3) δ 7.21 – 7.02 (m, 4H), 6.42 (d, J = 15.8 Hz, 1H), 6.26 (dt, J = 
15.8, 6.9 Hz, 1H), 2.48 – 2.38 (m, 3H), 2.34 (s, 3H), 2.29 (d, J = 6.1 Hz, 
1H), 1.96 (d, J = 3.8 Hz, 1H), 1.65 (dd, J = 13.7, 7.4 Hz, 2H), 1.48 (s, 
9H); 
13
C NMR (125 MHz, CDCl3) δ 162.47, 137.87, 137.44, 130.59, 
129.16, 128.30, 127.68, 126.59, 123.06, 80.83, 37.57, 32.11, 31.60, 30.36, 
27.85, 21.29; IR (KBr): 2982, 2933, 1711, 1313, 1161, 965 cm
-1
; HRMS 
(ESI) calcd for C18H25NNaO2 [M+Na] 
+




carboxylic acid (4.1d): []D
25
 +45.7 (c 1.0, CHCl3); 
1
H NMR (500 MHz, 
CDCl3) δ 7.40 (d, J = 8.4 Hz, 2H), 7.20 (d, J = 8.4 Hz, 2H), 6.37 (d, J = 
15.9 Hz, 1H), 6.26 (dt, J = 15.8, 6.8 Hz, 1H), 2.53 – 2.32 (m, 3H), 2.28 (d, 
J = 6.1 Hz, 1H), 1.94 (d, J = 3.8 Hz, 1H), 1.74 – 1.54 (m, 2H), 1.46 (s, 
9H); 
13
C NMR (125 MHz, CDCl3) δ 162.52, 136.52, 131.53, 130.39, 
129.46, 127.50, 120.59, 81.00, 37.53, 32.03, 31.71, 30.43, 27.92; IR 
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(KBr): 2978, 2931, 1716, 1309, 1161 cm
-1
; HRMS (ESI) calcd for 
C17H22BrNNaO2 [M+Na] 
+




carboxylic acid (4.1e): []D
25
 +39.5 (c 1.0, CHCl3); 
1
H NMR (500 MHz, 
CDCl3) δ 7.35 – 7.19 (m, 4H), 6.40 (d, J = 15.8 Hz, 1H), 6.25 (dt, J = 
15.8, 6.9 Hz, 1H), 2.46 – 2.37 (m, 3H), 2.29 (d, J = 6.1 Hz, 1H), 1.95 (d, 
J = 3.8 Hz, 1H), 1.71 – 1.55 (m, 2H), 1.47 (s, 9H); 13C NMR (125 MHz, 
CDCl3) δ 162.47, 136.05, 132.43, 130.20, 129.36, 128.53, 127.12, 80.92, 
37.49, 32.01, 31.65, 30.36, 27.87; IR (KBr): 2980, 2933, 1708, 1315, 
1153 cm
-1
; HRMS (ESI) calcd for C17H22ClNNaO2 [M+Na] 
+





carboxylic acid (4.1f): []D
25
 +41.6 (c 1.0, CHCl3); 
1
H NMR (500 MHz, 
CDCl3) δ 7.26 – 6.84 (m, 4H), 6.41 (d, J = 15.8 Hz, 1H), 6.29 (dt, J = 
15.7, 6.9 Hz, 1H), 2.49 – 2.35 (m, 3H), 2.28 (d, J = 6.0 Hz, 1H), 1.95 (d, 
J = 3.7 Hz, 1H), 1.75 – 1.57 (m, 2H), 1.46 (s, 9H); 13C NMR (125 MHz, 
CDCl3) δ 164.09, 162.56, 162.14, 140.01, 130.99, 129.91, 129.84, 129.61, 
121.87, 121.85, 113.82, 113.65, 112.47, 112.30, 81.06, 37.55, 32.05, 
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31.73, 30.39, 27.93; IR (KBr): 2978, 2933, 1712, 1316, 1151 cm
-1
; 
HRMS (ESI) calcd for C17H22FNNaO2 [M+Na] 
+





buten-1-yl)]-1-aziridine carboxylic acid (4.1g): []D
25
 +38.2 (c 1.0, 
CHCl3); 
1
H NMR (500 MHz, CDCl3) δ 7.95 (s, 1H), 7.81 (d, J = 7.7 Hz, 
1H), 7.49 (d, J = 7.7 Hz, 1H), 7.33 (t, J = 7.7 Hz, 1H), 6.47 (d, J = 15.7 
Hz, 1H), 6.32 (dt, J = 15.8, 6.9 Hz, 1H), 2.49 – 2.36 (m, 3H), 2.28 (d, J = 
6.1 Hz, 1H), 1.95 (d, J = 3.8 Hz, 1H), 1.69 – 1.61 (m, 2H), 1.59 (s, 9H), 
1.46 (s, 9H); 
13
C NMR (125 MHz, CDCl3) δ 165.76, 162.54, 137.70, 
132.25, 130.61, 129.87, 129.78, 128.33, 127.87, 126.92, 81.00, 37.59, 
32.07, 31.71, 30.42, 28.18, 27.93; IR (KBr): 2981, 2933, 1708, 1305, 
1160 cm
-1
; HRMS (ESI) calcd for C22H31NNaO4 [M+Na] 
+





1-aziridine carboxylic acid (4.1h): []D
25
 +41.8 (c 1.0, CHCl3); 
1
H 
NMR (500 MHz, CDCl3) δ 7.36 (d, J = 8.3 Hz, 2H), 7.33 (d, J = 8.3 Hz, 
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2H), 6.44 (d, J = 15.8 Hz, 1H), 6.28 (dt, J = 15.8, 6.9 Hz, 1H), 5.36 (s, 
1H), 3.31 (s, 6H), 2.46 – 2.35 (m, 3H), 2.27 (d, J = 6.1 Hz, 1H), 1.94 (d, J 
= 3.8 Hz, 1H), 1.66 – 1.58 (m, 2H), 1.45 (s, 9H); 13C NMR (125 MHz, 
CDCl3) δ 162.51, 137.72, 136.70, 130.19, 129.86, 126.83, 125.74, 102.91, 
80.92, 52.53, 37.58, 32.09, 31.66, 30.41, 27.89; IR (KBr): 2984, 2930, 
1711, 1312, 1160, 1101, 1054 cm
-1
; HRMS (ESI) calcd for C20H29NNaO4 
[M+Na] 
+








 +42.6 (c 1.0, CHCl3); 
1
H 
NMR (500 MHz, CDCl3) δ 7.60 (d, J = 7.1 Hz, 2H), 7.55 (d, J = 8.3 Hz, 
2H), 7.46 – 7.31 (m, 5H), 6.49 (d, J = 15.8 Hz, 1H), 6.32 (dt, J = 15.8, 
6.9 Hz, 1H), 2.51 – 2.39 (m, 3H), 2.30 (d, J = 6.1 Hz, 1H), 1.97 (d, J = 
3.8 Hz, 1H), 1.67 (ddd, J = 10.7, 7.4, 2.7 Hz, 2H), 1.48 (s, 9H);
 13
C NMR 
(125 MHz, CDCl3) δ 162.56, 140.77, 139.73, 136.63, 130.14, 129.66, 
128.72, 127.17, 126.85, 126.36, 80.97, 37.63, 32.17, 31.71, 30.49, 27.93; 
IR (KBr): 2980, 2937, 1712, 1314, 1156 cm
-1
; HRMS (ESI) calcd for 
C23H27NNaO2 [M+Na] 
+










 +41.1 (c 1.0, CHCl3); 
1
H 
NMR (500 MHz, CDCl3) δ 7.83 – 7.37 (m, 7H), 6.61 (d, J = 15.8 Hz, 1H), 
6.40 (dt, J = 15.7, 6.9 Hz, 1H), 2.51 – 2.43 (m, 3H), 2.30 (d, J = 6.0 Hz, 
1H), 1.97 (d, J = 3.8 Hz, 1H), 1.71 – 1.66 (dt, J = 14.3, 5.5 Hz, 2H), 1.47 
(s, 9H); 
13
C NMR (125 MHz, CDCl3) δ 162.60, 135.06, 133.67, 132.72, 
130.73, 129.99, 128.08, 127.82, 127.61, 126.15, 125.53, 125.47, 123.53, 
81.02, 37.68, 32.21, 31.75, 30.58, 27.95; IR (KBr): 2980, 2933, 1711, 
1313, 1159, 963 cm
-1
; HRMS (ESI) calcd for C21H25NNaO2 [M+Na] 
+
 : 




carboxylic acid (4.1k): []D
25
 +48.2 (c 1.0, CHCl3); 
1
H NMR (500 MHz, 
CDCl3) δ 7.33 – 7.00 (m, 3H), 6.48 (d, J = 15.8 Hz, 1H), 6.14 (dt, J = 
14.4, 7.0 Hz, 1H), 2.51 – 2.35 (m, 3H), 2.30 (d, J = 6.0 Hz, 1H), 1.97 (d, 
J = 3.7 Hz, 1H), 1.71 – 1.58 (m, 2H), 1.49 (s, 9H); 13C NMR (125 MHz, 
CDCl3) δ 162.51, 140.12, 129.35, 125.77, 124.86, 124.85, 120.62, 80.90, 
37.57, 32.11, 31.66, 30.27, 27.89; IR (KBr): 2982, 2934, 1711, 1314, 
1159, 963 cm
-1
; HRMS (ESI) calcd for C15H21NNaO2S [M+Na] 
+
 : 




4.6.3 General Procedure for Bromonium Ion Induced Aziridine Ring 
Expansion 
With the protection of nitrogen gas, into the freshly distilled ethyl acetate 
(1 mL) was added compound 4.1a (27 mg, 0.1 mmol), NsNH2 (30 mg, 
0.15 mmol), and recrystallized NBS (27 mg, 0.15 mmol) at -30 
o
C.  After 
stirring at this temperature for 48 h, the reaction was quenched by 
saturated Na2SO3 solution. The mixture was then extracted by EtOAc, 
washed with brine, dried and evaporated under reduced pressure. The 
residue was purified by column chromatography to provide product 4.2a. 
 
(2R, 3S, 6R)- N-Boc-3-bromo-6-nosylamino-2-phenyl-azepane (4.2a): 
[]D
25
  – 66.5 (c 1.0, CHCl3); 
1
H NMR (500 MHz, CDCl3) δ 8.34 (d, J = 
8.6 Hz, 2H), 8.10 (d, J = 8.6 Hz, 2H), 7.42 – 7.21 (m, 5H), 7.06 (bs, 1H), 
5.52 (d, J = 5.7 Hz, 1H), 4.65 (t, J = 6.9 Hz, 1H), 3.47 – 3.44 (m, 2H), 
2.82 (d, J = 12.2 Hz, 1H), 2.44 – 2.34 (m, 1H), 2.32 – 2.23 (m, 1H), 2.21 
– 2.11 (m, 1H), 1.89 – 1.77 (m, 1H), 1.53 (s, 9H); 13C NMR (125 MHz, 
CDCl3) δ 157.97, 149.89, 146.83, 138.27, 128.84, 128.25, 128.18, 126.80, 
124.32, 82.71, 65.53, 53.51, 53.43, 46.58, 32.62, 31.42, 28.25; IR (KBr): 
2981, 2934, 1664, 1532, 1411, 1349, 1164 cm
-1
; HRMS (ESI) calcd for 
C23H28BrN3NaO6S [M+Na] 
+





(2R, 3S, 6R)- N-Boc-3-bromo-2-(2-methylphenyl)-6-nosylamino-
azepane (4.2b): []D
25
  – 52.2 (c 1.0, CHCl3); 
1
H NMR (500 MHz, 
CDCl3) δ 8.31 (d, J = 8.4 Hz, 2H), 8.06 (d, J = 8.7 Hz, 2H), 7.24 – 7.10 
(m, 4H), 7.05 (bs, 1H), 5.72 (m, 1H), 4.98 (m, 1H), 3.54 (m, 1H), 3.19 (d, 
J = 15.5 Hz, 1H), 2.95 – 2.72 (m, 1H), 2.42 – 2.30 (m, 1H), 2.24 (s, 3H), 
2.19 – 2.16 (m, 2H), 1.99 – 1.93 (m, 1H), 1.54 (s, 9H); 13C NMR (125 
MHz, CDCl3) δ 157.22, 149.80, 147.35, 137.52, 136.21, 131.82, 128.29, 
128.07, 125.97, 125.92, 124.33, 82.41, 62.74, 55.20, 54.40, 46.32, 31.58, 
30.00, 28.22, 19.84; IR (KBr): 2981, 1669, 1532, 1409, 1350, 1161 cm
-1
; 
HRMS (ESI) calcd for C24H30BrN3NaO6S [M+Na]
+




(2R, 3S, 6R)- N-Boc-3-bromo-2-(3-methylphenyl)-6-nosylamino-
azepane (4.2c): []D
25
  – 81.9 (c 1.0, CHCl3); 
1
H NMR (500 MHz, 
CDCl3) δ 8.33 (d, J = 8.7 Hz, 2H), 8.09 (d, J = 8.7 Hz, 2H), 7.23 – 7.01 
(m, 5H), 5.48 (d, J = 5.7 Hz, 1H), 4.66 (t, J = 6.4 Hz, 1H), 3.52 – 3.38 (m, 
2H), 2.83 (dd, J = 15.6, 3.6 Hz, 1H), 2.40 – 2.36 (m, 1H), 2.32 (s, 3H), 
2.31 – 2.23 (m, 1H), 2.18 – 2.13 (m, 1H), 1.91 – 1.77 (m, 1H), 1.54 (s, 
9H); 
13
C NMR (125 MHz, CDCl3) δ 157.98, 149.86, 146.84, 138.51, 
138.14, 128.89, 128.68, 128.22, 127.54, 124.30, 123.80, 82.62, 65.47, 
53.51, 53.46, 46.54, 32.59, 31.42, 28.25, 21.53; IR (KBr): 2981, 1668, 
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1532, 1410, 1349, 1166 cm
-1
; HRMS (ESI) calcd for C24H30BrN3NaO6S 
[M+Na] 
+
 : 590.0931, found: 590.0955. 
 
 
(2R, 3S, 6R)- N-Boc-3-bromo-2-(4-bromophenyl)-6-nosylamino-
azepane (4.2d): []D
25
  – 57.9 (c 1.0, CHCl3); 
1
H NMR (500 MHz, 
CDCl3) δ 8.34 (d, J = 8.7 Hz, 2H), 8.10 (d, J = 8.7 Hz, 2H), 7.45 (d, J = 
8.4 Hz, 2H), 7.10 (d, J = 8.3 Hz, 2H), 6.92 (bs, 1H), 5.34 (d, J = 6.6 Hz, 
1H), 4.48 (t, J = 7.4 Hz, 1H), 3.52 – 3.43 (m, 2H), 2.84 (d, J = 15.0 Hz, 
1H), 2.43 – 2.36 (m, 1H), 2.32 – 2.23 (m, 1H), 2.21 – 2.16 (m, 1H), 1.86 
– 1.74 (m, 1H), 1.51 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 157.69, 
149.93, 146.58, 137.56, 131.88, 128.56, 128.26, 124.34, 122.16, 82.99, 
65.34, 53.24, 52.82, 46.73, 33.03, 31.75, 28.23; IR (KBr): 2980, 1669, 
1532, 1409, 1349, 1164 cm
-1
; HRMS (ESI) calcd for C23H27Br2N3NaO6S 
[M+Na] 
+
 : 653.9880, found: 653.9895. 
 
 
(2R, 3S, 6R)- N-Boc-3-bromo-2-(4-chlorophenyl)-6-nosylamino-
azepane (4.2e): []D
25
  – 75.6 (c 1.0, CHCl3); 
1
H NMR (500 MHz, 
CDCl3) δ 8.34 (d, J = 8.7 Hz, 2H), 8.10 (d, J = 8.7 Hz, 2H), 7.30 (d, J = 
8.4 Hz, 2H), 7.16 (d, J = 8.4 Hz, 2H), 6.93 (bs, 1H), 5.37 (d, J = 6.7 Hz, 
1H), 4.48 (t, J = 7.4 Hz, 1H), 3.56 – 3.38 (m, 2H), 2.84 (d, J = 14.4 Hz, 
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1H), 2.43 – 2.36 (m, 1H), 2.32 – 2.24 (m, 1H), 2.23 – 2.14 (m, 1H), 1.85 
– 1.74 (m, 1H), 1.51 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 157.71, 
149.94, 146.60, 137.04, 134.07, 128.93, 128.24, 124.35, 82.98, 65.28, 
53.25, 52.90, 46.71, 33.02, 31.75, 28.24; IR (KBr): 2980, 1669, 1532, 
1408, 1349, 1163 cm
-1
; HRMS (ESI) calcd for C23H27BrClN3NaO6S 
[M+Na] 
+
 : 610.0385, found: 610.0405. 
 
 
(2R, 3S, 6R)- N-Boc-3-bromo-2-(3-fluorophenyl)-6-nosylamino-
azepane (4.2f): []D
25
  – 60.2 (c 1.0, CHCl3); 
1
H NMR (500 MHz, 
CDCl3) δ 8.34 (d, J = 8.6 Hz, 2H), 8.10 (d, J = 8.6 Hz, 2H), 7.09 (m, 5H), 
5.41 (d, J = 6.3 Hz, 1H), 4.52 (t, J = 7.2 Hz, 1H), 3.56 – 3.37 (m, 2H), 
2.83 (d, J = 14.2 Hz, 1H), 2.43 – 2.36 (m, 1H), 2.32 – 2.24 (m, 1H), 2.20 
– 2.16 (m, 1H), 1.87 – 1.75 (m, 1H), 1.52 (s, 9H); 13C NMR (125 MHz, 
CDCl3) δ 163.83, 161.87, 157.70, 149.93, 146.64, 141.01, 140.96, 130.37, 
130.31, 128.26, 124.35, 122.39, 115.26, 115.09, 114.29, 114.12, 83.02, 
65.35, 53.27, 52.77, 46.79, 32.95, 31.66, 28.23; IR (KBr): 2981, 1663, 
1532, 1409, 1349, 1166 cm
-1
; HRMS (ESI) calcd for C23H27BrFN3NaO6S 
[M+Na] 
+





(2R, 3S, 6R)- N-Boc-3-bromo-2-(3-tert-butyl carboxylicphenyl)-6-
nosylamino-azepane (4.2g): []D
25
  – 71.6 (c 1.0, CHCl3); 
1
H NMR (500 
MHz, CDCl3) δ 8.34 (d, J = 8.7 Hz, 2H), 8.10 (d, J = 8.7 Hz, 2H), 7.96 – 
7.35 (m, 4H), 6.94 (bs, 1H), 5.42 (d, J = 6.8 Hz, 1H), 4.55 (t, J = 7.6 Hz, 
1H), 3.59 – 3.38 (m, 2H), 2.89 (d, J = 15.2 Hz, 1H), 2.54 – 2.37 (m, 1H), 
2.32 – 2.22 (m, 2H), 1.89 – 1.73 (m, 1H), 1.58 (s, 9H), 1.52 (s, 9H); 13C 
NMR (125 MHz, CDCl3) δ 165.17, 157.74, 149.93, 146.57, 138.92, 
132.54, 131.15, 129.24, 128.63, 128.29, 127.61, 124.34, 82.94, 81.53, 
65.66, 53.27, 52.79, 46.57, 33.15, 31.89, 28.25, 28.14; IR (KBr): 2980, 
1707, 1668, 1533, 1411, 1349, 1307, 1164 cm
-1
; HRMS (ESI) calcd for 
C28H36BrN3NaO8S [M+Na] 
+
 : 676.1299, found: 676.1299. 
 
(2R, 3S, 6R)- N-Boc-3-bromo-2-(4-formylphenyl)-6-nosylamino-
azepane (4.2h): []D
25
  – 58.5 (c 1.0, CHCl3); 
1
H NMR (500 MHz, 
CDCl3) δ 9.99 (s, 1H), 8.35 (d, J = 8.7 Hz, 2H), 8.10 (d, J = 8.7 Hz, 2H), 
7.85 (d, J = 8.2 Hz, 2H), 7.42 (d, J = 8.0 Hz, 2H), 6.81 (bs, 1H), 5.37 (d, 
J = 6.9 Hz, 1H), 4.50 (t, J = 7.7 Hz, 1H), 3.69 – 3.36 (m, 3H), 3.05 – 2.77 
(m, 1H), 2.52 – 2.39 (m, 1H), 2.34 – 2.18 (m, 2H), 1.89 – 1.75 (m, 1H), 
1.49 (s, 9H); 
13
C NMR (125 MHz, CDCl3) δ 191.33, 149.97, 146.48, 
145.39, 136.03, 129.97, 128.28, 127.65, 124.36, 83.19, 65.95, 53.13, 
52.41, 47.26, 33.15, 32.08, 28.21; IR (KBr): 2980, 1699, 1664, 1533, 
1410, 1349, 1164 cm
-1
; HRMS (ESI) calcd for C24H28BrN3NaO7S 
[M+Na]
+





(2R, 3S, 6R)- N-Boc-3-bromo-6-nosylamino-2-(4-phenylphenyl)-
azepane (4.2i): []D
25
  – 60.3 (c 1.0, CHCl3); 
1
H NMR (500 MHz, CDCl3) 
δ 8.34 (d, J = 8.7 Hz, 2H), 8.11 (d, J = 8.7 Hz, 2H), 7.60 – 7.28 (m, 9H), 
7.08 (bs, 1H); 5.56 (d, J = 5.7 Hz, 1H), 4.68 (t, J = 6.5 Hz, 1H), 3.50 – 
3.47 (m, 2H), 2.88 (d, J = 13.5 Hz, 1H), 2.44 – 2.37 (m, 1H), 2.35 – 2.25 
(m, 1H), 2.21 – 2.17 (m, 1H), 1.89 – 1.86 (m, 1H), 1.55 (s, 9H); 13C 
NMR (125 MHz, CDCl3) δ 157.94, 149.87, 146.79, 141.06, 140.02, 
137.12, 128.85, 128.23, 127.64, 127.44, 127.24, 126.95, 124.31, 82.75, 
65.35, 53.48, 53.39, 46.65, 32.69, 31.44, 28.26; IR (KBr): 2980, 1664, 
1532, 1410, 1349, 1164 cm
-1
; HRMS (ESI) calcd for C29H32BrN3NaO6S 
[M+Na] 
+
 : 652.1087, found: 652.1084. 
 
 
(2R, 3S, 6R)- N-Boc-3-bromo-2-(naphthalene-2-yl)-6-nosylamino-
azepane (4.2j): []D
25
  – 90.4 (c 1.0, CHCl3); 
1
H NMR (500 MHz, 
CDCl3) δ 8.31 (d, J = 8.7 Hz, 2H), 8.08 (d, J = 8.6 Hz, 2H), 7.82 – 7.77 
(m, 3H), 7.64 (s, 1H), 7.54 – 7.45 (m, 2H), 7.28 – 7.26 (m, 1H), 7.08 (bs, 
1H), 5.70 (d, J = 5.1 Hz, 1H), 4.86 (t, J = 6.2 Hz, 1H), 3.44 – 3.41 (m, 
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2H), 2.92 – 2.79 (m, 1H), 2.50 – 2.38 (m, 1H), 2.36 – 2.27 (m, 1H), 2.25 
– 2.22 (m, 1H), 1.96 – 1.82 (m, 1H), 1.56 (s, 9H); 13C NMR (125 MHz, 
CDCl3) δ 157.96, 149.85, 146.84, 135.55, 132.91, 132.78, 128.89, 
128.21, 127.89, 127.61, 126.69, 126.63, 125.50, 124.85, 124.31, 82.77, 
65.57, 53.63, 53.44, 46.60, 32.28, 31.30, 28.28; IR (KBr): 2982, 1666, 
1532, 1411, 1350, 1167 cm
-1
; HRMS (ESI) calcd for C27H30BrN3NaO6S 
[M+Na]
+
 : 626.0931, found: 626.0941. 
 
 
(2R, 3S, 6S)- N-Boc-3-bromo-6-nosylamino-2-(thiophene-3-yl)-
azepane (4.2k): []D
25
  – 69.3 (c 1.0, CHCl3); 
1
H NMR (500 MHz, 
CDCl3) δ 8.33 (d, J = 8.8 Hz, 2H), 8.09 (d, J = 8.8 Hz, 2H), 7.30 (dd, J = 
5.0, 2.9 Hz, 1H), 7.16 – 7.05 (m, 2H), 6.89 (dd, J = 5.0, 0.8 Hz, 1H), 5.58 
(d, J = 5.1 Hz, 1H), 4.57 (t, J = 5.9 Hz, 1H), 3.43 – 3.39 (m, 2H), 2.75 
(dd, J = 15.2, 3.2 Hz, 1H), 2.40 – 2.29 (m, 1H), 2.29 – 2.20 (m, 1H), 2.14 
– 2.05 (m, 1H), 1.88 – 1.76 (m, 1H), 1.54 (s, 9H); 13C NMR (125 MHz, 
CDCl3) δ 157.73, 149.85, 146.87, 139.06, 128.22, 126.82, 126.45, 124.31, 
122.09, 82.72, 62.42, 54.13, 53.47, 46.32, 32.47, 30.89, 28.23; IR (KBr): 
2980, 1664, 1532, 1410, 1349, 1164 cm
-1
; HRMS (ESI) calcd for 
C21H26BrN3NaO6S2 [M+Na]
+





(2S, 3R, 5R)- N-Boc-3-bromo-5-nosylamino-2-phenyl-piperidine 
(4.14): []D
25
  +17.6 (c 1.0, CHCl3); 
1
H NMR (500 MHz, CDCl3) δ 8.38 
(d, J = 8.7 Hz, 2H), 8.07 (d, J = 8.7 Hz, 2H), 7.38 – 7.12 (m, 5H), 5.61 (s, 
1H), 5.05 (d, J = 2.3 Hz, 1H), 4.44 (d, J = 8.5 Hz, 1H), 4.26 (dd, J = 13.4, 
4.4 Hz, 1H), 4.01 – 3.94 (m, 1H), 2.54 – 2.45 (m, 1H), 2.14 (d, J = 13.5 
Hz, 1H), 1.78 (ddd, J = 14.3, 11.6, 3.1 Hz, 1H), 1.47 (s, 9H). 
13
C NMR 
(125 MHz, CDCl3) δ 155.11, 150.22, 146.56, 136.32, 129.28, 128.19, 
127.78, 126.00, 124.61, 81.22, 59.28, 49.21, 46.46, 44.43, 35.83, 28.27; 
IR (KBr): 2928, 1672, 1531, 1349, 1166cm
-1
; HRMS (ESI) calcd for 
C22H26BrN3NaO6S [M+Na] 
+
 : 562.0618, found: 562.0631. 
 
(2S*, 3R*, 5R*)-  N-Ts-3-bromo-5-nosylamino-2-phenyl-piperidine 
(4.14-Ts): m.p.: 187 – 189 oC; 1H NMR (500 MHz, CDCl3) δ 8.32 (d, J = 
8.8 Hz, 2H), 7.93 (d, J = 8.9 Hz, 2H), 7.75 (d, J = 8.3 Hz, 2H), 7.37 – 
7.20 (m, 7H), 5.49 (s, 1H), 4.91 (d, J = 2.3 Hz, 1H), 4.62 (d, J = 8.0 Hz, 
1H), 3.91 (dd, J = 13.6, 4.5 Hz, 1H), 3.74 – 3.63 (m, 1H), 2.90 (dd, J = 
13.6, 11.1 Hz, 1H), 2.48 (s, 3H), 1.89 (d, J = 14.0 Hz, 1H), 1.73 – 1.65 
(m, 1H). 
13
C NMR (125 MHz, CDCl3) δ 150.18, 145.91, 143.86, 136.86, 
135.86, 129.53, 129.26, 128.17, 128.08, 127.74, 126.54, 124.52, 62.04, 
48.97, 46.43, 46.06, 35.10, 21.60; IR (KBr): 2958, 1535, 1340, 1163, 
1092 cm
-1
; HRMS (ESI) calcd for C24H24BrN3NaO6S2 [M+Na] 
+
 : 




4.6.4 Compound 4.2a-Bn Preparation 
 
Into the CH3CN (3 mL) solution of compound 4.2a (100 mg, 0.18 mmol) 
and LiOH (25 mg, 0.6 mmol) was added n-PrSH (46 mg, 0.6 mmol). The 
mixture was stirred at r.t. for 6 h till the complete consumption of starting 
material. After that, BnBr (70 mg, 0.4 mmol) was added and the mixture 
was stirred at r.t. overnight. After usual work-up, compound 4.2a-Bn was 
obtained via column chromatography as colorless solid (50 mg, 61%) 
(2R, 3S, 6R)- N-Boc-3-bromo-6-benzylamino-2-phenyl-azepane (4.2a-
Bn): []D
25




H NMR (500 
MHz, CDCl3) δ 7.45 – 7.22 (m, 10H), 5.09 (d, J = 9.0 Hz, 1H), 4.98 (t, J 
= 7.6 Hz, 1H), 3.88 (s, 2H), 3.73 – 3.64 (m, 1H), 3.61 (m, 1H), 2.89 – 
2.82 (m, 2H), 2.49 – 2.39 (m, 1H), 2.19 – 2.11 (m, 1H), 1.91 (m, 2H), 
1.29 (s, 9H); 
13C NMR (125 MHz, DMSO) δ 166.15, 140.41, 128.92, 
128.61, 128.51, 128.31, 127.80, 127.09, 126.19, 83.67, 67.03, 61.65, 
57.61, 55.35, 51.42, 28.96, 28.23, 23.50; IR (KBr): 2976, 1692, 1454, 
1367, 1161 cm
-1
; HRMS (ESI) calcd for C24H32BrN2O2 [M+H] 
+
 : 







4.6.5 Synthetic Applications 
 
Into the CH2Cl2 (5 mL) solution of compound 4.2a (100 mg, 0.18 mmol) 
was added TFA (0.15 mL, 2.0 mmol) at 0 
o
C. After stirring r.t. for 8 h, 
the solvent together with excessive TFA was evaporated under vacuum. 
The product obtained was dissolved again in CH2Cl2 (5 mL). 5 % K2CO3 
solution (2 mL) was then added. The reaction mixture was stirred 
vigorously at r.t. for 6 h. The organic phase obtained was the CH2Cl2 
solution of compound 4.3, which was used directly in the next step 
without concentration. 
Into the CH2Cl2 solution of compound 4.3 obtained above was added 
AcOH (0.1 mL). After stirring at r.t. for 8 h, saturated NaHCO3 solution 
(2 mL) was added. The reaction mixture was then extracted with CH2Cl2, 
dried (Na2SO4) and evaporated under reduced pressure. Purification of 
the residue by column chromatography gave product 4.4 as colorless oil 




  + 24.9 (c 1.0, CHCl3); 
1
H NMR (500 MHz, CDCl3) δ 8.31 
(d, J = 8.8 Hz, 2H), 8.03 (d, J = 8.7 Hz, 2H), 7.41 – 7.28 (m, 5H), 5.83 
(bs, 1H), 5.47 (d, J = 7.7 Hz, 1H), 3.53 (s, 1H), 2.82 (ddd, J = 10.6, 7.8, 
2.6 Hz, 1H), 2.64 – 2.54 (m, 2H), 2.05 (s, 3H), 1.74 (d, J = 13.4 Hz, 1H), 
1.69 – 1.61 (m, 1H), 1.52 – 1.42 (m, 1H), 1.36 – 1.27 (m, 1H); 13C NMR 
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(125 MHz, CDCl3) δ 169.86, 149.76, 147.35, 137.27, 128.62, 128.60, 
127.98, 127.46, 124.30, 78.17, 59.45, 50.81, 48.14, 29.22, 23.19, 21.06; 
IR (KBr): 2955, 1737, 1532, 1350, 1164 cm
-1
; HRMS (ESI) calcd for 
C20H24N3O6S [M+H]
+
 : 434.1385, found: 434.1380. 
Into the CH2Cl2 solution of compound 4.3 was added 4-fluorothiophenol 
(29 L, 0.27 mmol). After stirring at r.t. for 2 h, the reaction mixture was 
extracted with CH2Cl2, dried (Na2SO4) and evaporated under reduced 
pressure. Purification of the residue by column chromatography gave 
product 4.6 as colorless oil (75 mg, 83%) 
(S)-((2R,5R)-5-(Nosylamino)piperidin-2-yl)-phenylmethyl-4-
fluorophenyl thioether (4.6): []D
25
  + 93.4 (c 1.0, CHCl3); 
1
H NMR 
(500 MHz, CDCl3) δ 8.32 (d, J = 8.7 Hz, 2H), 8.02 (d, J = 8.7 Hz, 2H), 
7.31 – 6.82 (m, 9H), 5.73 (bs, 1H), 3.87 (d, J = 8.4 Hz, 1H), 3.56 (s, 1H), 
2.84 (ddd, J = 10.9, 8.5, 2.5 Hz, 1H), 2.62 (s, 2H), 2.07 – 1.94 (m, 1H), 
1.81 (d, J = 13.7 Hz, 1H), 1.62 – 1.47 (m, 1H), 1.38 – 1.27 (m, 1H); 13C 
NMR (125 MHz, CDCl3) δ 163.58, 161.60, 149.82, 147.42, 138.90, 
135.85, 135.79, 128.58, 128.57, 127.97, 127.76, 124.31, 115.97, 115.80, 
60.48, 59.19, 51.20, 48.27, 29.80, 25.71; IR (KBr): 2956, 1533, 1489, 
1350, 1161 cm
-1
; HRMS (ESI) calcd for C24H25FN3O4S2 [M+H]
+
 : 
502.1280, found: 502.1265. 
Into the CH2Cl2 solution of compound 4.3 was added 
azidotrimethylsilane (48 L, 0.36 mmol) and water (33 L, 1.8 mmol). 
After stirring at r.t. for 8 h, the reaction mixture was extracted with 
CH2Cl2, dried (Na2SO4) and evaporated under reduced pressure. 
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Purification of the residue by column chromatography gave product 4.9 
as colorless oil (63 mg, 84%) 
(S)-((2R,5R)-5-(Nosylamino)piperidin-2-yl)-phenylmethyl azide (4.9): 
[]D
25
  + 61.3 (c 1.0, CHCl3); 
1
H NMR (500 MHz, CDCl3) δ 8.32 (d, J = 
8.6 Hz, 2H), 8.03 (d, J = 8.6 Hz, 2H), 7.43 – 7.27 (m, 5H), 5.74 (d, J = 
5.9 Hz, 1H), 4.20 (d, J = 8.2 Hz, 1H), 3.53 (s, 1H), 2.66 (ddd, J = 10.8, 
8.3, 2.4 Hz, 1H), 2.57 (s, 2H), 1.87 – 1.71 (m, 2H), 1.48 (tt, J = 13.8, 3.6 
Hz, 1H), 1.33 – 1.20 (m, 1H); 13C NMR (126 MHz, CDCl3) δ 149.82, 
147.30, 136.27, 129.06, 129.03, 127.99, 127.85, 124.34, 70.43, 59.77, 
50.85, 48.12, 29.34, 23.97; IR (KBr): 2955, 2104, 1533, 1350, 1164 cm
-1
; 
HRMS (ESI) calcd for C18H21N6O4S [M+H]
+




Into the CH2Cl2 (2 mL) solution of compound 4.4 (50 mg, 0.12 mmol) 
and TEA (34 L, 0.24 mol) was added TsCl (34 mg, 0.18 mmol). The 
reaction mixture was stirred at r.t. overnight. After usual workup the 
crude product was purified by column chromatography to afford 









(500 MHz, CDCl3) δ 8.36 (d, J = 8.8 Hz, 2H), 8.07 (d, J = 8.8 Hz, 2H), 
7.42 – 7.27 (m, 5H), 7.00 (d, J = 8.1 Hz, 2H), 6.87 (d, J = 8.2 Hz, 2H), 
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5.94 (d, J = 10.2 Hz, 1H), 4.71 (d, J = 7.0 Hz, 1H), 4.55 (dd, J = 10.1, 4.6 
Hz, 1H), 3.41 (d, J = 10.9 Hz, 2H), 2.66 (dd, J = 15.6, 12.4 Hz, 1H), 2.35 
(s, 3H), 2.06 (s, 3H), 1.94 – 1.91 (m, 1H), 1.83 – 1.76 (m, 1H), 1.71 – 
1.63 (m, 1H); 
13
C NMR (125 MHz, CDCl3) δ 169.94, 150.16, 146.03, 
143.57, 137.46, 135.66, 129.45, 128.76, 128.70, 128.40, 127.45, 127.41, 
124.52, 71.88, 53.42, 48.69, 46.14, 26.92, 24.74, 21.45, 21.14; IR (KBr): 
2957, 1744, 1531, 1456, 1351, 1291, 1227, 1152, 1088, 1026 954 cm
-1
;  
HRMS (ESI) calcd for C27H29N3NaO8S2 [M+Na]
+




Into the CH3CN (5 mL) solution of compound 4.6 (50 mg, 0.1 mmol) was 
added K2CO3 (41 mg, 0.3 mmol) and 1,2-dibromoethane (86 L, 1 
mmol). The reaction mixture was refluxed until TLC indicates 
disappearance of the reactants. After usual workup the crude product was 
purified by column chromatography to afford compound 4.7 as colorless 




  + 24.6 (c 1.0, CHCl3); 
1
H NMR 
(500 MHz, CDCl3) δ 8.36 (d, J = 8.5 Hz, 2H), 7.99 (d, J = 8.6 Hz, 2H), 
7.21 – 6.77 (m, 9H), 3.90 (d, J = 10.2 Hz, 1H), 3.74 (s, 1H), 3.47 (td, J = 
11.8, 5.0 Hz, 1H), 3.42 – 3.30 (m, 2H), 3.08 (d, J = 14.4 Hz, 1H), 2.95 (d, 
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J = 13.8 Hz, 1H), 2.85 (d, J = 13.7 Hz, 1H), 2.73 (ddd, J = 14.6, 11.3, 6.1 
Hz, 1H), 2.31 – 2.26 (m, 1H), 2.06 (dd, J = 15.0, 3.5 Hz, 1H), 1.91 – 1.83 
(m, 1H), 1.72 – 1.63 (m, 1H); 13C NMR (125 MHz, CDCl3) δ 163.80, 
161.82, 149.97, 145.70, 140.09, 136.80, 136.74, 128.20, 128.11, 128.00, 
127.10, 124.41, 115.79, 115.61, 62.55, 59.49, 55.59, 45.44, 43.95, 42.29, 





calcd for C26H27FN3O4S2 [M+H]
+
: 528.1441, found: 528.1422. 
 
 
Into the THF (5 mL) solution of compound 4.6 (50 mg, 0.1 mmol) was 
added K2CO3 (41 mg, 0.3 mmol) and bromoacetyl bromide (17 L, 0.2 
mmol). The reaction mixture was refluxed until TLC indicates 
disappearance of the reactants. After usual workup the crude product was 
purified by column chromatography to afford compound 4.8 as clear oil. 




 –11.1 (c 1.0, CHCl3); 
 1
H 
NMR (500 MHz, CDCl3) δ 8.39 (d, J = 8.7 Hz, 2H), 8.00 (d, J = 8.7 Hz, 
2H), 7.23 – 6.79 (m, 9H), 4.88 (d, J = 11.5 Hz, 1H), 3.97 (d, J = 13.7 Hz, 
2H), 3.49 (dd, J = 16.6, 6.8 Hz, 1H), 3.37 (d, J = 13.5 Hz, 1H), 3.21 (d, J 
= 14.6 Hz, 1H), 3.01 (d, J = 14.5 Hz, 1H), 2.42 – 2.34 (m, 1H), 2.27 – 
2.25 (m, 1H), 1.96 – 1.87 (m, 1H), 1.86 – 1.77 (m, 1H); 13C NMR (125 
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MHz, CDCl3) δ 175.91, 163.69, 161.71, 150.30, 143.90, 140.40, 136.12, 
136.05, 128.32, 128.24, 127.93, 127.13, 124.71, 115.92, 115.75, 70.42, 
57.35, 53.24, 50.87, 50.14, 31.30, 25.28; IR (KBr): 3021, 1699, 1532, 
1489, 1351, 1165 cm
-1
; HRMS (ESI) calcd for C26H24FN3NaO5S2 
[M+Na]
+
: 564.1040, found: 564.1034. 
 
 
Into the THF (5 mL) solution of compound 4.9 (50 mg, 0.12 mmol) was 
added Ph3P (47 mg, 0.18 mmol) and water (22 L, 1.2 mmol). The 
reaction mixture was refluxed for 4 h. After usual workup the crude 
product was purified by column chromatography to afford compound 




H NMR (500 MHz, CDCl3) δ 8.31 (d, J = 8.9 Hz, 2H), 8.02 (d, J 
= 8.5 Hz, 2H), 7.38 – 7.27 (m, 5H), 3.71 (d, J = 7.1 Hz, 1H), 3.52 (s, 1H), 
2.65 – 2.51 (m, 3H), 1.76 (d, J = 13.6 Hz, 1H), 1.70 (dd, J = 12.7, 2.9 Hz, 
1H), 1.51 – 1.42 (m, 1H), 1.35 – 1.27 (m, 1H); 13C NMR (125 MHz, 
CDCl3) δ 149.79, 147.52, 142.55, 128.68, 128.00, 127.79, 127.27, 124.30, 
62.24, 60.66, 51.09, 48.37, 29.68, 23.17; IR (KBr): 3430, 3020, 1647, 
1532, 1350, 1163 cm
-1
; HRMS (ESI) calcd for C18H23N4O4S [M+H]
+
: 
391.1435, found: 391.1446. 
Into the CH2Cl2 (5 mL) solution of compound 4.10 (40 mg, 0.1 mmol) 
and TEA (42 L, 0.3 mmol) was added triphosgene (15 mg, 0.05 mmol). 
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The reaction mixture was stirred at r.t. for 2 h. After usual workup the 
crude product was purified by column chromatography to afford 






 +78.2 (c 1.0, CHCl3); 
1
H NMR (500 
MHz, CDCl3) δ 8.27 (d, J = 8.8 Hz, 2H), 8.05 (d, J = 8.9 Hz, 2H), 7.43 – 
7.30 (m, 5H), 6.65 (d, J = 5.3 Hz, 1H), 5.39 (bs, 1H), 4.93 (d, J = 8.5 Hz, 
1H), 3.85 (d, J = 13.9 Hz, 1H), 3.76 (ddd, J = 11.9, 8.6, 3.4 Hz, 1H), 3.41 
(s, 1H), 2.91 (dd, J = 13.9, 3.0 Hz, 1H), 2.00 (dd, J = 11.5, 2.8 Hz, 1H), 
1.47 (tt, J = 14.0, 3.1 Hz, 1H), 1.29 – 1.14 (m, 1H), 0.89 – 0.80 (m, 1H); 
13
C NMR (125 MHz, CDCl3) δ 161.76, 149.85, 146.53, 136.87, 128.78, 
128.42, 128.34, 126.83, 124.27, 58.95, 57.60, 47.86, 45.34, 28.08, 20.28; 
IR (KBr): 3022, 2928, 2856, 1693, 1531, 1464, 1349, 1164 cm
-1
; HRMS 
(ESI) calcd for C19H19N4O5S [M-H]
-
: 415.1082, found: 415.1081. 
 
4.6.6 HPLC Results 
Racemic-4.2a was separated by Daicel Chiralpak IA, i-PrOH/hexane = 
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5.1 Bromonium Ion Induced Epoxide Ring Opening 
 
An efficient, regioselective bromonium ion induced epoxide ring opening 
reaction was developed using epichlorohydrin, olefin, nosyl amide, and NBS 
as the four components. As the most simple cyclic ether and vital synthon in 
organic chemistry, a series of unsymmetric epoxides were screened. 
Epichlorohydrin gave the most promising result with high regioselectivity of 
the aminoethylether product. Upon treatment of potassium carbonate, the 
product could be transformed easily to functionalized 2-chloromethyl 
morpholine compound.  
 
Compared with epoxides bearing electron donating groups, epichlorohydrin 
gave the anti-Markovnikov products with up to 10:1 regioselectivity. This 
selectivity could be due to the strong electronegativity of the chlorine atom, 
which means electronic effect plays a more important role in the system than 
steric effect. Low temperature also favored anti-Markovnikov regio-isomer 
because it was kinetically controlled product. 
 
Due to the competition with nosyl amide, which is the second nucleophile, 
excessive epichlorohydrin should be applied in the reaction system. 
Sometimes it was used even as the solvent, which is obviously uneconomic. 
However, epichlorohydrin could be easily distilled from the reaction mixture 
and reused at least three times without affecting the yield or the 
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regioselectivity. Another limitation lies in the stereoselectivity of the reaction. 
When unsymmetric olefin was used, no stereoselectivity was observed yet. 
Due to the effectiveness and usefulness of this novel reaction, stereoselectivity 
is worth further research.  
 
This study is the first to develop a regioselective bromonium ion induced 
epoxide ring opening reaction. The finding is significant since this novel 
methodology could be easily applied in the preparation of highly 
functionalized morpholines, which is an important pharmacophore often 
encountered in drugs or drug-like molecules. Apart from that, the methylene 
chloride handles in morpholine ring could be readily derivatized to yield other 
functional molecules. When enantiopure epichlorohydrin was applied, the 
corresponding optical pure morpholine was accomplished, which provided a 
feasible approach for enantiopure morpholine synthesis.  
 
5.2 Syntheis of Carnitine Acetyltransferase Inhibitor and Reboxetine 
 
To further explore the potential of the regioselective bromonium ion induced 
epoxide ring opening reaction to provide functionalized morpholines, the 
synthesis of 3.1, an Carnitine Acetyltransferase Inhibitor first reported in 1995, 
was studied. Starting from simple symmetric olefin, which could be prepared 
easily from commercial compound in 3 steps in over 90 % yield, the final 
enatiopure morpholine salt was synthesized in 11 steps in overall 13 % yield. 
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After the easy assembly of the morpholine ring using our methodology, the 
scaffold of the final product was constructed. The key step of the total 
synthesis lay in the differentiation of the two hydroxyl groups at – 78 oC using 
n-BuLi as the base. The equatorial hydroxyl group was selectively 
deprotonated and protected by Ts group using this condition (9:1), probably 
due to the intramolecular hydrogen bond formed between the axil hydroxyl 
group and the nitrogen atom, forming a stable six member ring. After the 
reduction of the OTs group, the entiopure morpholine salt was prepared. The 
physical and spectroscopic data of 3.1 are in full agreement with the literature 
report. 
 
One of the limitations of the total synthesis is that only 30 % yield was 
obtained during the transformation of compound 3.8 to 3.9. Despite the 
relatively low yield of transformation, there was hardly any side reaction. 65 % 
of starting material was recovered and could be reused without affecting 
enatiopurity. Another limitation is that the overall yield of this synthetic route 
is lower compared with reported procedure. However, the 1995 report started 
from a chiral amino alcohol that was not commercially available and took at 
least 5 steps of preparation. Using our strategy, the chiral center was derived 
from (S)-epichlorohydrin, which was commercially available. 
 
This study showed an alternative method for the preparation of enatiopure 
morpholine 3.1. As a convergent multicomponent methodology, this strategy 
has been shown to be effective in the preparation of versatile C-functionalized 
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morpholines. This advantage could be applied in the pharmaceutical industry 
for the preparation of morpholine compound pool. 
 
5.3 Bromonium Ion Induced Aziridine Ring Expansion 
 
A multicomponent, efficient, stereoselective and atom-economical bromonium 
ion induced aziridine ring expansion cascade was developed. Due to the highly 
strained ring system of activated aziridine, the lone pair of nitrogen can hardly 
resonate with neighboring Boc group, which results in a certain degree of 
nucleophilicity of aziridine. After the activation of olefin, aziridine worked as 
nucleophile to attack bromonium ion, leading to aziridinium intermediate. 
Nosyl amide then acted as the second nucleophile to react with the 
intermediate to afford fuctionalized piperidine compound. 
 
The starting aziridine was prepared from simple Glutamic acid, followed by 
reacting with benzaldehyde using Wittig-Schlosser Modification. This strategy 
was proved to be highly efficient for the synthesis of styrene type aziridine 
stereoselectively, (trans : cis >= 10 : 1). Another advantage of this synthetic 
route is that starting from the sample Glutamic acid, using Wittig Reaction, 
cis-product could also be obtained as the major product. The novel bromonium 
ion induced aziridinium ring expansion reaction provided azepanes with high 
stereoselectivity, probably due to the more stable aziridinium intermediate.  
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This methodology provided an efficient strategy for the preparation of 
functionalized azepanes. Although not the focus of current research yet, the 
study on electronic effect of the reaction should provide more insightful result 
on the scope and mechanism of the reaction. This remains an interesting area 
and requires attention for future extended research. Due to the capability of 
this novel reaction to construct aza-cyclic ring system, it should be applied in 








































































































































































































































































































































































































































































COSY of 4.2b 
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